<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934. FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1998.
Commission file number 333-43529
---------
LJL BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 77-0360183
(State or other jurisdiction (I.R.S. Employer
of incorporation or Identification
organization) Number)
404 TASMAN DRIVE 94089
SUNNYVALE, CA
(Address of principal (Zip Code)
executive offices)
(408) 541-8787
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes No X
---- ----
As of April 1, 1998, 10,296,133 shares of the Registrant's Common Stock,
$0.001 par value, were issued and outstanding.
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
LJL BIOSYSTEMS, INC.
INDEX
<TABLE>
<CAPTION>
PAGE NO.
--------
<S> <C> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Condensed Balance Sheets As of March 31, 1998 and December 31, 1997 . . . . . . . . . . . 3
Condensed Statements of Operations for the Three Months Ended March 31, 1998 and 1997 . . . 4
Condensed Statements of Cash Flows for the Three Months Ended March 31, 1998 and 1997 . . 5
Notes to Condensed Financial Statements. . . . . . . . . . . . . . . . . . . . . . . . . . 6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations . . . . 9
PART II. OTHER INFORMATION
Item 1. Legal Proceedings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Item 2. Changes in Securities and Use of Proceeds. . . . . . . . . . . . . . . . . . . . . . . . . 24
Item 3. Defaults Upon Senior Securities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Item 4. Submission of Matters to a Vote of Securities Holders. . . . . . . . . . . . . . . . . . . 25
Item 5. Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Item 6. Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
</TABLE>
-2-
<PAGE>
PART I.
ITEM 1. CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
LJL BIOSYSTEMS, INC
CONDENSED BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1998 1997
----------------------------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 8,886,000 $ 5,525,000
Short-term investments 6,978,000 -
Accounts receivable 186,000 59,000
Inventories 553,000 283,000
Other current assets 67,000 484,000
----------------------------------
Total current assets 16,670,000 6,351,000
Property and equipment, net 514,000 442,000
-----------------------------------
$ 17,184,000 $ 6,793,000
-----------------------------------
-----------------------------------
LIABILITIES, MANDATORILY REDEEMABLE CONVERTIBLE
PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable $ 678,000 $ 681,000
Accrued expenses 514,000 360,000
Customer deposits 180,000 153,000
Current portion of long-term debt - 46,000
-----------------------------------
Total current liabilities 1,372,000 1,240,000
Long-term debt, net of current portion - 40,000
-----------------------------------
Mandatorily redeemable convertible preferred
stock; redemption value $21,543,000 - 9,308,000
-----------------------------------
Stockholders' (deficit) equity:
Common stock 10,000 5,000
Additional paid-in capital 22,586,000 705,000
Deferred stock compensation (746,000) (755,000)
Accumulated deficit (6,038,000) (3,750,000)
-----------------------------------
Total stockholders' (deficit) equity 15,812,000 (3,795,000)
-----------------------------------
$ 17,184,000 $ 6,793,000
-----------------------------------
-----------------------------------
</TABLE>
-3-
<PAGE>
LJL BIOSYSTEMS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
1998 1997
---------------------------------
<S> <C> <C>
REVENUES:
Product sales $ 320,000 $ 2,362,000
Development agreements - 214,000
---------------------------------
Total revenues 320,000 2,576,000
---------------------------------
COSTS AND OPERATING EXPENSES:
Product sales 289,000 1,137,000
Research and development 1,417,000 530,000
Selling, general and administrative 716,000 464,000
---------------------------------
Total costs and operating expenses 2,422,000 2,131,000
---------------------------------
Income (loss) from operations (2,102,000) 445,000
Interest income, net 68,000 26,000
---------------------------------
Income (loss) before provision for income taxes (2,034,000) 471,000
Provision for income taxes - 10,000
---------------------------------
Net income (loss) (2,034,000) 461,000
Accretion of mandatorily redeemable
convertible preferred stock redemption value (254,000) -
---------------------------------
Net income (loss) available to common stockholders $ (2,288,000) $461,000
---------------------------------
---------------------------------
Net income (loss) per share available to common
stockholders:
Basic $ (0.39) $ 0.10
Diluted $ (0.39) $ 0.10
Proforma $ (0.23) $ -
Shares used in computation of net income (loss)
per share available to common stockholders:
Basic 5,815,952 4,500,500
Diluted 5,815,952 4,823,069
Proforma 8,672,915
</TABLE>
-4-
<PAGE>
LJL BIOSYSTEMS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
1998 1997
-----------------------------------
<S> <C> <C>
Cash flows from operating activities:
Net income (loss) $ (2,034,000) $ 461,000
Adjustments to reconcile net income
(loss) to net cash used in
operating activities:
Depreciation and amortization 58,000 23,000
Stock compensation expense 43,000 -
Changes in assets and liabilities:
Accounts receivable (127,000) (194,000)
Inventories (270,000) 276,000
Other current assets 417,000 (2,000)
Accounts payable (3,000) (8,000)
Accrued expenses 154,000 78,000
Customer deposits 27,000 (1,033,000)
-----------------------------------
Net cash used in operating activities (1,735,000) (399,000)
-----------------------------------
Cash flows used in investing activities for the
Purchase of property and equipment (130,000) (54,000)
Purchase of short-term investments (6,978,000) -
-----------------------------------
Net cash used in investing activities (7,108,000) (54,000)
-----------------------------------
Cash flows from financing activities:
Repayment of long-term debt (86,000) (7,000)
Proceeds from issuance of common stock,net 12,290,000 -
-----------------------------------
Net cash provided by (used in) financing
activities 12,204,000 (7,000)
-----------------------------------
Net increase (decrease) in cash and cash
equivalents 3,361,000 (460,000)
Cash and cash equivalents at beginning of period 5,525,000 1,166,000
-----------------------------------
Cash and cash equivalents at end of period $ 8,886,000 $ 706,000
-----------------------------------
-----------------------------------
SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING
ACTIVITIES:
Issuance of common stock upon conversion of
mandatorily redeemable convertible
preferred stock $ 9,562,000 $ -
</TABLE>
-5-
<PAGE>
LJL BIOSYSTEMS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
NOTE 1 - BASIS OF PRESENTATION:
In the opinion of LJL BioSystems, Inc. (the "Company"), the accompanying
unaudited financial data contain all adjustments, consisting only of normal
recurring adjustments, which the Company considers necessary to present fairly
the financial information included therein. This Quarterly Report on Form 10-Q
should be read in conjunction with the audited financial statements and notes
thereto included in the Prospectus constituting part of Form S-1 dated March 13,
1998 as filed with the Securities and Exchange Commission. The interim results
presented herein are not necessarily indicative of the results of operations
that may be expected for the full fiscal year ending December 31, 1998, or any
other future period.
NOTE 2 - INVENTORIES:
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1998 1997
---- ----
<S> <C> <C>
Raw materials $ 368,000 $ 278,000
Work-in-process 180,000 -
Finished goods 5,000 5,000
---------- ----------
$ 553,000 $ 283,000
---------- ----------
---------- ----------
</TABLE>
NOTE 3 - INITIAL PUBLIC OFFERING:
On March 13,1998, the Company completed its initial public offering ("IPO")
of 2,000,000 shares of Common Stock at $7.00 per share, with the Company
receiving proceeds, net of underwriting commissions and associated costs, of
$12.2 million. In April 1998, the Company sold an additional 88,000 shares of
common stock in connection with the exercise of an over-allotment option granted
to the underwriters and received proceeds, net of underwriting commissions and
associated costs, of approximately $573,000. Upon the closing of the IPO all
the outstanding shares of Mandatorily Redeemable Convertible Preferred Stock
(the "Preferred Stock") converted into an equal number of shares of Common
Stock.
-6-
<PAGE>
NOTE 4 - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE AVAILABLE TO COMMON
STOCKHOLDERS:
The Company adopted SFAS No. 128, "Earnings per Share", during the fiscal
year ended December 31, 1997 and retroactively restated all prior periods. Basic
earnings per share is computed using the weighted average number of common
shares outstanding during the period. Diluted earnings per share is computed
using the weighted average number of common and potential common shares
outstanding during the period. Potential common shares consist of the
incremental common shares issuable upon conversion of outstanding convertible
preferred stock (using the if-converted method) and shares issuable upon the
exercise of stock options and warrants (using the treasury stock method).
Potential common shares are excluded from the computation if their effect is
anti-dilutive, as was the case for the quarter ended March 31, 1998. For the
quarter ended March 31, 1998, net (loss) available to common stockholders
includes $254,000 to reflect accretion of the Preferred Stock redemption value.
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
1998 1997
----------------------------
<S> <C> <C>
Basic
Net income (loss) $ (2,034,000) $ 461,000
Accretion of manditorily redeemable
convertible preferred stock redemption
value (254,000)
Net income (loss) available to common ----------------------------
shareholders $ (2,288,000) $ 461,000
----------------------------
----------------------------
Weighted average common shares outstanding 5,815,952 4,500,500
----------------------------
----------------------------
Basic net income (loss) per share $ (0.39) $ 0.10
----------------------------
Diluted
Net income (loss) $ (2,034,000) $ 461,000
Accretion of manditorily redeemable
convertible preferred stock redemption
value (254,000)
----------------------------
Net income (loss) available to common
shareholders $ (2,288,000) $ 461,000
----------------------------
Weighted average common shares outstanding 5,815,952 4,500,500
Dilutive Options 322,569
----------------------------
Total shares 5,815,952 4,823,069
----------------------------
Diluted net income (loss) per share $ (0.39) $ 0.10
----------------------------
</TABLE>
-7-
<PAGE>
NOTE 5 - PRO FORMA NET INCOME (LOSS) PER SHARE:
Pro forma net (loss) per share for the quarter ended March 31, 1998 was
calculated using the weighted average number of common shares outstanding during
the period adjusted for the assumed conversion as of January 1, 1998 of all
outstanding shares of Preferred Stock into 3,621,503 shares of common stock.
There is no comparable pro forma calculation for the quarter ended March 31,
1997 due to the fact that the Preferred Stock was not issued until June 1997.
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
1998 1997
----------------------------
<S> <C> <C>
----------------------------
Net income (loss) $ (2,034,000)
----------------------------
Weighted average common shares outstanding 5,815,952
Assumed conversion of preferred stock 3,621,503
Less preferred stock included in weighted
average common share calculation (764,540)
---------------------------
Total shares 8,672,915
---------------------------
---------------------------
Proforma net income (loss) per share $ (0.23)
---------------------------
</TABLE>
NOTE 6 - COMPREHENSIVE INCOME:
In June 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 130 (SFAS No. 130), "Reporting Comprehensive
Income." SFAS 130 establishes standards for the reporting of comprehensive
income and its components in interim and annual financial statements of the
Company beginning in fiscal 1999. Comprehensive income, as defined, includes all
changes in equity (net assets) during a period from non-owner sources.
Reclassification of financial statements for earlier periods for comparative
purposes is required. Adoption by the Company in fiscal 1999 is not expected to
have a significant effect on the Company's financial statements.
-8-
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THE DISCUSSION BELOW CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS THAT ARE BASED
ON THE BELIEFS OF THE COMPANY'S MANAGEMENT, AS WELL AS ASSUMPTIONS MADE BY, AND
INFORMATION CURRENTLY AVAILABLE TO, THE COMPANY'S MANAGEMENT. THE COMPANY'S
FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS COULD DIFFER MATERIALLY FROM THOSE
EXPRESSED IN, OR IMPLIED BY, ANY SUCH FORWARD-LOOKING STATEMENTS. THE COMPANY
ASSUMES NO OBLIGATION TO UPDATE SUCH FORWARD-LOOKING STATEMENTS. SEE "RISK
FACTORS" FOR A DISCUSSION OF CERTAIN FACTORS, AMONG OTHERS, WHICH COULD CAUSE OR
CONTRIBUTE TO SUCH MATERIAL DIFFERENCES. THE FOLLOWING PRESENTATION OF
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS SHOULD BE READ IN CONJUNCTION WITH THE COMPANY'S FINANCIAL STATEMENTS
AND NOTES THERETO AND OTHER FINANCIAL INFORMATION INCLUDED THEREIN.
OVERVIEW
From inception in 1988 through 1991, the Company derived its revenues from
the development of clinical diagnostics and research instruments for customers.
Beginning in 1992, the Company began manufacturing and shipping these clinical
diagnostics and research instruments to customers either for their internal use
or for resale on an OEM basis.
In the second half of 1996, the Company implemented a new strategic
business model aimed at developing products for the emerging high throughput
screening market of the accelerated drug discovery market by leveraging its
existing technology platform and product development and manufacturing expertise
into this new market. In connection with this change in strategy, the Company
shifted its focus from developing and manufacturing original equipment
manufacturing ("OEM") clinical diagnostics and research products to developing,
manufacturing and marketing its own products for high throughput screening. As
part of its shift in focus, the Company has de-emphasized its OEM development
activities and has phased out production of all but one of its OEM instruments.
However, the Company expects to continue to manufacture products under its
agreement with Ventana Medical Systems, Inc. ("Ventana") through 1998 and
possibly beyond. As a result, revenues from development agreements have declined
significantly, and revenues from OEM product sales are expected to materially
decline in future periods.
RESULTS OF OPERATIONS
REVENUES. Total revenues decreased by $2.3 million, from $2.6 million for
the quarter ended March 31, 1997 to $0.3 million for the quarter ended March 31,
1998. Revenues recognized under development agreements for OEM products,
decreased from $0.2 million during the quarter ended March 31, 1997 to $0
during the quarter ended March 31, 1998, due to the Company's decision in 1996
to focus its future efforts on internal development of a proprietary HTS product
platform and not to pursue additional development or manufacturing agreements
for OEM products. Revenues from OEM product sales decreased by $2.1 million,
from $2.4 million during the quarter ended March 31, 1997 to $0.3 million for
the quarter
-9-
<PAGE>
ended March 31, 1998, due to the Company's increasing focus on the HTS market
and the phasing out of the Luminometer (a microplate reader), the Q2000 (a
clinical analyzer) and the microplate heater products. As of March 31, 1998,
the Horizon (a clinical specimen processor), manufactured under an agreement
with Ventana, was the only OEM product still being manufactured. Although the
Company expects to continue to manufacture Horizon through 1998 and possibly
beyond under its agreement with Ventana, OEM product sales are expected to
continue to substantially decline in future periods. In addition, the Company
does not expect revenues from development agreements in future periods.
COST OF PRODUCT SALES. Cost of product sales decreased from $1.1 million
for the quarter ended March 31, 1997 to $300,000 for the quarter ended
March 31, 1998, due to decreased unit sales of the Luminometer, Q2000 and
microplate heater products. Gross profit, as a percentage of product sales,
decreased from 52% during the quarter ended March 31, 1997 to 10% for the
quarter ended March 31, 1998, primarily as a result of decreased absorption of
manufacturing overhead resulting from reduced unit sales. The Company expects
that per unit cost of sales will remain roughly constant or increase and gross
profit to continue at a low percentage of product sales in future periods, as
unit sales of OEM products continue to decrease, resulting in decreased
absorption of manufacturing overhead. In addition, cost of product sales of
Analyst is expected to be high for at least several years as a result of low
absorption of manufacturing overhead resulting from low production volume.
RESEARCH AND DEVELOPMENT. Research and development expense increased from
$0.5 million for the quarter ended March 31, 1997 to $1.4 million for the
quarter ended March 31, 1998. This increase was primarily due to increased costs
associated with the development of the Company's HTS product platform, partially
offset by a decrease in the level of research and development expenses incurred
in connection with development agreements for OEM customers. The Company expects
research and development expenditures to increase significantly in future
periods to support the development of its HTS products.
SELLING, GENERAL AND ADMINISTRATIVE. Selling, general and administrative
costs increased from $0.5 million for the quarter ended March 31, 1997 to
$0.7 million for the quarter ended March 31, 1998. This increase was primarily
due to increases in marketing and sales expenses associated with the addition of
sales and marketing personnel and HTS product marketing expenses and other
increases in general and administrative expenses. The Company expects selling,
general and administrative expenses to increase substantially in future periods
due to the increased marketing and selling resources necessary to promote the
Company's HTS products, as well as additional administrative costs associated
with being a public company.
-10-
<PAGE>
INTEREST AND OTHER INCOME, NET. Net interest and other income increased
from $28,000 for the quarter ended March 31, 1997 to $78,000 for the quarter
ended March 31, 1998. This increase was primarily due to interest earned on
higher levels of invested cash, cash equivalents and short-term investments.
INCOME TAXES
Prior to June 1997, the Company had been taxed as an S corporation for
federal and state income tax purposes. Under the Internal Revenue Code
provisions regarding S corporations, the Company had not been subject to federal
income taxes but had been subject to state income taxes at a reduced rate. As an
S corporation, the Company's stockholders paid taxes on their share of the
Company's taxable income in their individual tax returns. In June 1997, in
connection with the Company's Preferred Stock financing, the Company became
subject to the C corporation provisions of the Internal Revenue Code pursuant to
which the Company's earnings are taxed for federal and state income tax purposes
at the corporate level. Through June 1997, the Company's profits were
distributed to the Company's stockholders through a combination of compensation,
which was treated as expense in the Statement of Operations, and dividends.
Future distributions are not expected. No provision for income taxes has been
recognized for the quarter ended March 31, 1998, as the Company incurred net
operating losses for income tax purposes and has no carryback potential.
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 1998, the Company had cash, cash equivalents and short-term
investments of $15.9 million and an accumulated deficit of $6.0 million. The
Company completed its initial public offering of Common Stock in March 1998,
raising approximately $12.2 million of cash, net of underwriting discounts and
associated costs. Prior to that, the Company satisfied its liquidity needs
primarily through cash flows generated from operations, private sales of
Preferred Stock, and to a lesser extent, from bank loans for equipment purchases
and loans from stockholders.
Net cash used in operating activities totaled $1.7 million and $0.4 million
during the quarters ended March 31, 1998 and March 31, 1997 respectively. The
increase in net cash used in operating activities is primarily due to the
Company's net loss during the quarter ended March 31, 1998 compared to net
income earned during the quarter ended March 31, 1997.
Cash used in investing activities totaled $7.1 million and $0.1 million
during the quarters ended March 31, 1998 and March 31, 1997 respectively. The
increase in cash used in investing activities is primarily due to the
Company's investment of $7.0 million in short-term, investment grade,
interest-bearing financial instruments. These financial instruments, like all
fixed income instruments, are subject to interest rate risk and will fall in
value if market interest rates increase. The Company attempts to limit this
exposure by investing in short-term investments.
-11-
<PAGE>
In February 1998, the Company entered into an equipment financing agreement
that provides a $1.3 million line of credit that can be used to finance
purchases of equipment, computers and software necessary to support the
Company's HTS development effort and additions to the marketing, sales and
administrative infrastructure. As of March 31, 1998, the Company had not drawn
down against this line of credit.
In June 1997, the Company entered into a development, license and sales
agreement with FluorRx under which it obtained worldwide rights to certain
patented assay technologies. Future minimum royalty payments due through 2002
under the agreement would amount to approximately $1.0 million. The source of
funds for these royalty payments is expected to be the sales proceeds from the
sale of HTS products developed by LJL pursuant to the agreement.
The Company may be required to raise substantial additional capital over
a period of several years in order to develop and commercialize its products.
The Company's future capital requirements will depend on numerous factors,
including the costs associated with developing and commercializing its
products, developing a direct marketing and sales force, maintaining
existing, or entering into future licensing and distribution agreements,
protecting intellectual property rights, entering the reagents and assay kits
business, expanding facilities and consummating possible future acquisitions
of technologies, products or businesses. The Company believes that its cash,
cash equivalents and short-term investments, combined with cash to be
generated from operations, will be sufficient to fund operations for the next
twelve to eighteen months. The Company may consume available resources more
rapidly than currently anticipated, resulting in the need for additional
funding. The Company may be required to raise additional capital through a
variety of sources, including the public equity market, private equity
financings, collaborative arrangements, and public or private debt. There can
be no assurance that additional capital will be available on favorable terms,
if at all. If adequate funds are not available, the Company may be required
to significantly reduce or refocus its operations or to obtain funds through
arrangements that may require the Company to relinquish rights to certain of
its products, technologies or potential markets, which could have a material
adverse effect on the Company's business, financial condition and results of
operations. To the extent that additional capital is raised through the sale
of equity, the issuance of such securities would result in ownership dilution
to the Company's existing stockholders.
CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS OF OPERATIONS
The Company desires to take advantage of the "Safe Harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and of Section 21E and Rule
3b-6 under the Securities Exchange Act of 1934. Specifically, the Company
wishes to alert readers that the following important factors, as well as other
factors including, without limitation, those described elsewhere in this Report,
could in the future affect, and in the past have affected, the Company's actual
results and could cause the Company's results for future periods to differ
materially from those
-12-
<PAGE>
expressed in any forward-looking statements made by or on behalf of the
Company. The Company assumes no obligation to update such forward-looking
statements.
NEW BUSINESS STRATEGY; NEW AND UNDEFINED MARKET FOR HIGH THROUGHPUT SCREENING
PRODUCTS
In the second half of 1996, the Company implemented a new strategic
business model to develop products for the HTS market. In connection with
this change in strategy, the Company shifted its focus from developing and
manufacturing clinical diagnostic and research products on an original
equipment manufacturing ("OEM") basis to developing, manufacturing and
marketing products for the HTS market. As a result, the Company's historical
operating and financial performance is not indicative of future financial and
business results. The Company incurred operating losses for the quarter ended
March 31, 1998 as a result of its change in business strategy and expects
that operating losses will increase substantially in future quarters due to a
significant decline in revenues and a substantial increase in expenditures to
develop and commercialize the Company's HTS products. The Company anticipates
that it will continue to incur losses for at least the next several years.
The Company has only recently begun commercial shipments of its first HTS
instrument, Analyst. Accordingly, the Company is subject to the risks
inherent in the operation of a new business, such as the failure to develop
an effective sales, marketing and distribution channel, failure to achieve
market acceptance and demand for its HTS products, failure to implement
commercial scale-up of developed HTS products, if any, and failure to attract
and retain key personnel. Furthermore, the HTS market is new and undefined,
and the use of HTS by pharmaceutical and biotechnology companies is limited.
Demand for the Company's HTS products will depend upon the extent to which
pharmaceutical and biotechnology companies adopt HTS as a drug discovery
tool. If HTS does not become a widely used method in drug discovery, demand
for the Company's products will not develop as the Company currently expects
or at all. The lack of demand for the Company's HTS products would have a
material adverse effect on the Company's business, financial condition and
results of operations.
EARLY STAGE OF INSTRUMENTATION DEVELOPMENT
The Company's success will depend on its ability to develop and
commercialize its HTS instruments. The Company has only recently begun
commercial shipments of it's first HTS instrument, ANALYST. The Company has not
previously developed or commercialized products for the HTS market. Much of the
instrumentation and software expected to be incorporated into the Company's HTS
products has not previously been used in HTS applications. The successful
implementation and operation of the Company's HTS products will be a complex
process requiring the integration of advanced robotics, microfluidics, automated
storage and retrieval systems, fluorescence detector technologies and software
and information systems. Even if ANALYST appears to be promising at an early
stage of development or at commercial launch, it may not achieve market
acceptance. In addition, ANALYST may be difficult or uneconomical to produce,
fail to achieve expected performance levels, have a price level that is
unacceptable in the industry or be precluded from commercialization
-13-
<PAGE>
by the proprietary rights of others. There can be no assurance that the
Company will be able to successfully develop, manufacture and market ANALYST
or any other HTS products on a timely basis, achieve anticipated performance
levels or throughputs, gain industry acceptance of the Company's products or
develop a profitable business. The failure to achieve any of these objectives
would have a material adverse effect on the Company's business, financial
condition and results of operations.
RISKS ASSOCIATED WITH THE DEVELOPMENT AND COMMERCIALIZATION OF REAGENTS AND
ASSAY KITS
The Company expects that a substantial portion of its revenues will be
derived from the sale of reagents and assay kits. The Company has no experience
in the development, manufacture or marketing of reagents or assay kits. The
Company intends to license assay technologies from third parties and to develop
reagents and assay kits internally. There can be no assurance that the Company
will succeed in licensing any additional assay technologies on acceptable terms,
if at all, or that it will successfully commercialize any reagents that it
licenses. In addition, the Company is internally developing reagents and assay
kits, but has no previous experience in this area. There can be no assurance
that the Company will successfully develop reagents or assay kits internally or
that, if developed, such reagents and assay kits will achieve market acceptance.
The Company currently intends to outsource the manufacture of reagents and
assays kits. There can be no assurance that the Company will be able to enter
into agreements with third parties for the manufacture of reagents and assay
kits on terms commercially favorable to the Company or at all. In addition, the
Company intends to sell reagents and assay kits to purchasers of HTS
instruments, including ANALYST. There can be no assurance that sales of ANALYST
will be sufficient to support this strategy. A failure to achieve commercial
acceptance of its reagents and assay kits would have a material adverse effect
on the Company's business, financial condition and results of operations.
DEPENDENCE ON NEW PRODUCTS; RAPID TECHNOLOGICAL CHANGE
The pharmaceutical and biotechnology instrumentation and reagents market is
characterized by rapid technological change and frequent new product
introductions. The Company's future success will depend on its ability to
enhance its current and planned HTS products and to develop and introduce, on a
timely basis, new products that address the evolving needs of its customers
including its higher-density, ultra high throughput analyzer and microplates and
its fluorescence-based reagents and assay kits. The Company does not anticipate
that prototypes for these ultra high throughput products will be available for
several years, if at all. Production of an ultra high throughput analyzer and
associated microplates, fluorescence-based reagents and assay kits will present
significant development and manufacturing challenges. The Company may experience
difficulties that could delay or prevent the successful development,
introduction and marketing of its new products or its product enhancements. Any
failure to develop and introduce products in a timely manner in response to
changing market demands or customer requirements could have a material adverse
effect on the Company's business, financial condition and results of operations.
-14-
<PAGE>
LACK OF SALES AND MARKETING EXPERIENCE
The Company has limited experience in direct marketing, sales or
distribution. The Company's future profitability will depend on its ability to
further develop a direct sales force to sell its HTS products to pharmaceutical
and biotechnology companies. The Company's products are technical in nature and
the Company therefore believes it is necessary to develop a direct sales force
consisting of people with scientific backgrounds and expertise. Competition for
such employees is intense. There can be no assurance that the Company will be
able to attract and retain qualified salespeople or that the Company will be
able to build an efficient and effective sales and marketing organization.
Failure to attract or retain qualified salespeople or to build such a sales and
marketing organization would have a material adverse effect on the Company's
business, financial condition and results of operations.
The Company intends to market its HTS products in certain international
markets through distributors. The Company does not currently have distributors
in any international markets, and there can be no assurance that the Company
will be able to engage qualified distributors. Such distributors, if engaged,
may fail to satisfy financial or contractual obligations to the Company, fail to
adequately market the Company's products, cease operations with little or no
notice to the Company or offer, design, manufacture or promote competing product
lines. The failure to develop and maintain effective distribution channels could
have a material adverse effect on the Company's business, financial condition
and results of operations.
COMPETITION
The market for HTS products is highly competitive. The Company expects that
competition will increase significantly as more biotechnology and pharmaceutical
companies adopt high throughput screening instruments as a drug discovery tool
and as new companies enter the market with advanced technologies and products.
The Company will compete in many areas, including high throughput screening
instruments, assay development and reagent sales. The Company competes with
companies which directly market HTS products. In addition, pharmaceutical and
biotechnology companies, academic institutions, governmental agencies and other
research organizations are conducting research and developing products in
various areas which compete with the Company's technology platform, either on
their own or in collaboration with others. Many of these competitors have
greater financial, operational and sales and marketing resources, and more
experience in research and development, than the Company. Further, certain
companies offer screening services on a contract or collaborative basis, and
these services could eliminate the need for a potential customer to purchase the
Company's products. The Company's technological approaches may be rendered
obsolete or uneconomical by advances in existing technological approaches or the
development of different approaches by one or more of the Company's current or
-15-
<PAGE>
future competitors. Many of these competitors have greater financial and
personnel resources, and more experience in research and development, sales
and marketing and other areas than the Company.
CONCENTRATION OF HTS MARKET
The market for HTS products is highly concentrated, with approximately 50
large pharmaceutical companies operating a substantial portion of the Company's
targeted drug discovery laboratories. Accordingly, the Company expects a
relatively small number of customers will account for a substantial portion of
its revenues. The Company will face risks associated with a highly concentrated
customer base when and if it begins to sell its HTS products, including the
failure to establish or maintain relationships within a limited customer pool,
or substantial financial difficulties or decreased capital spending by its
customers, any of which could have a material adverse effect on the Company's
business, financial condition and results of operations. Further, the Company
faces the risk that customers will negotiate price discounts or other
unfavorable terms, which could have a material adverse effect on the Company's
business, financial condition and results of operations.
LENGTHY SALES CYCLE
The sale of HTS products typically involves a significant technical
evaluation and commitment of capital by customers. Accordingly, the sales cycle
associated with the Company's HTS products is expected to be lengthy and subject
to a number of significant risks, including customers' budgetary constraints and
internal acceptance reviews, that are beyond the Company's control. Due to this
lengthy and unpredictable sales cycle, the Company's operating results could
fluctuate significantly from quarter to quarter.
MANUFACTURING RISK
The Company has never manufactured HTS products in commercial quantities.
The Company may encounter difficulties in scaling up production of its HTS
products relating to, among other things, quality control and assurance,
component supply and availability of qualified personnel. There can be no
assurance that, even if successfully developed and introduced to market, any of
the Company's products can be manufactured in sufficient quantities while
meeting quality control standards or at acceptable cost. Difficulties
encountered by the Company in manufacturing scale-up could have a material
adverse effect on its business, financial condition and results of operations.
-16-
<PAGE>
MANAGEMENT OF GROWTH
The Company's success will depend on the expansion of its operations and
the effective management of growth, which will place a significant strain on the
Company's management, operational and financial resources. To manage such
growth, the Company must expand its facilities, augment its operational,
financial and management systems and hire and train additional qualified
personnel. The Company's failure to manage growth effectively would have a
material adverse effect on the Company's business, financial condition and
results of operations.
DEPENDENCE UPON KEY PERSONNEL; NEED TO HIRE ADDITIONAL QUALIFIED PERSONNEL
The Company's success will depend to a significant degree upon the
continued services of key management, technical, and scientific personnel,
including Lev J. Leytes, the Company's Chairman of the Board of Directors,
President and Chief Executive Officer. In addition, the Company's success will
depend on its ability to attract and retain other highly skilled personnel.
Competition for qualified personnel is intense, and the process of hiring such
qualified personnel is often lengthy. There can be no assurance that the Company
can recruit such personnel on a timely basis, if at all. The Company's
management and other employees may voluntarily terminate their employment with
the Company at any time. The loss of the services of key personnel, or the
inability to attract and retain additional qualified personnel, could have a
material adverse effect on the Company's business, financial condition and
results of operations.
DEPENDENCE ON SUPPLIERS AND CONTRACT MANUFACTURERS
Certain components used in the Company's HTS instruments are currently
purchased from a single or a limited number of outside sources. The reliance on
a sole or limited number of suppliers could result in time delays associated
with redesigning a product due to a failure to obtain a single source component,
an inability to obtain an adequate supply of required components and reduced
control over pricing, quality and timely delivery. The Company does not maintain
long-term agreements with any of its suppliers, and therefore the supply of a
particular component could be terminated at any time without penalty to the
supplier. Any interruption in supply of single source components could have a
material adverse effect on the Company's business, financial condition and
results of operations. The Company intends to rely on contract manufacturers,
some of which may be single-source vendors, for the development, manufacture and
supply of certain of its reagents and assay kits. There can be no assurance the
Company will be able to enter into such manufacturing contracts on commercially
reasonable terms, if at all, or that the Company's current or future contract
manufacturers will meet the Company's requirements for quality, quantity or
timeliness. If the supply of any such instrumentation components, reagents or
assay kits is interrupted, components, reagents and assay kits from alternative
suppliers and contract
-17-
<PAGE>
manufacturers may not be available in sufficient volumes within required
timeframes, if at all, to meet the Company's production needs.
ACCUMULATED DEFICIT; UNCERTAINTY OF FUTURE PROFITABILITY
As of March 31, 1998, the Company had an accumulated deficit of
approximately $6.0 million. To date, the Company has not yet generated any
revenue from its HTS products, and the Company's expansion of its operations and
continued development of its HTS products will require a substantial increase in
marketing and sales and research and development expenditures for at least the
next several years. As a result, the Company expects to incur substantial
operating losses for the next several years. The Company's profitability will
depend on its ability to successfully develop and commercialize its HTS
products. Accordingly, the extent of future losses and the time required to
achieve profitability, if achieved at all, is highly uncertain. Moreover, if
profitability is achieved, the level of such profitability cannot be predicted
and may vary significantly from quarter to quarter.
FUTURE CAPITAL NEEDS; UNCERTAINTY OF ADDITIONAL FUNDING
The Company may be required to raise substantial additional capital over a
period of several years in order to develop and commercialize its products. The
Company's future capital requirements will depend on numerous factors, including
the costs associated with developing and commercializing its products,
developing a direct marketing and sales force, maintaining existing, or entering
into future, licensing and distribution agreements, protecting intellectual
property rights, entering the reagents and assay kits business, expanding
facilities and consummating possible future acquisitions of technologies,
products or businesses. The Company may consume available resources more rapidly
than currently anticipated, resulting in the need for additional funding. The
Company may be required to raise additional capital through a variety of
sources, including the public equity market, private equity financings,
collaborative arrangements, and public or private debt. There can be no
assurance that additional capital will be available on favorable terms, if at
all. If adequate funds are not available, the Company may be required to
significantly reduce or refocus its operations or to obtain funds through
arrangements that may require the Company to relinquish rights to certain of its
products, technologies or potential markets, which would have a material adverse
effect on the Company's business, financial condition and results of operations.
To the extent that additional capital is raised through the sale of equity, the
issuance of such securities would result in ownership dilution to the Company's
existing stockholders.
RISK OF INTERNATIONAL SALES AND OPERATIONS
The Company expects that international sales will account for a significant
portion of the Company's total revenues. International sales and operations are
subject to a number of risks, including the imposition of government
-18-
<PAGE>
controls, export license requirements, restrictions on the export of critical
technology, political and economic instability or conflicts, trade
restrictions, changes in tariffs and taxes, difficulties in staffing and
managing international operations, problems in establishing or managing
distributor relationships and general economic conditions. In addition, as
the Company expands its international operations, it may be required to
invoice its sales in local currencies. Consequently, fluctuations in the
value of foreign currencies relative to the U.S. dollar may adversely affect
the Company's business, financial condition and results of operations.
RISKS ASSOCIATED WITH POTENTIAL ACQUISITIONS OF TECHNOLOGIES AND BUSINESSES
The Company may acquire certain technologies, products or businesses to
broaden the scope of its existing and planned product lines and technologies.
Such acquisitions would expose the Company to the risks associated with the
assimilation of new technologies, operations, sites and personnel, the diversion
of resources from the Company's existing business and technologies, the
inability to generate revenues to offset associated acquisition costs, the
maintenance of uniform standards, controls, and procedures and the impairment of
relationships with employees and customers as a result of any integration of new
management personnel. Acquisitions may also result in the issuance of dilutive
equity securities, the incurrence or assumption of debt or additional expenses
associated with amortization of acquired intangible assets or potential
businesses. The Company's failure to successfully address such risks could have
a material adverse effect on the Company's business, financial condition and
results of operations.
INTELLECTUAL PROPERTY RISKS
The Company's success will depend in part on its ability to obtain patents,
maintain trade secret protection and operate without infringing the proprietary
rights of others. The Company has three U.S. patents. The Company has filed four
U.S. patent applications and seven provisional patent applications, all of which
are currently pending. To supplement its proprietary technology, the Company has
licensed ten patents from FluorRx, Inc. ("FluorRx") pursuant to a June 1997
agreement. Under this license, the Company obtained certain worldwide rights
relating to FluorRx's FLARe technology. Certain of these rights have been
licensed on an exclusive basis. Certain other rights have been licensed on a
non-exclusive basis, and therefore could be or are licensed to third parties. In
accordance with such agreement, the Company pays one-time fees as well as
royalties based on sales of its products that incorporate this technology. The
license may be terminated in the event of a material breach by the Company.
Furthermore, FluorRx may elect to convert the exclusive rights into
non-exclusive rights in the event the Company fails to make certain minimum
royalty payments. If the license were terminated by FluorRx due to a material
breach of the license by the Company, the Company would lose the right to
incorporate FLARe technology into its HTS products. In such event, the Company
would be required to exclude FLARe technology from the Company's existing and
future products and either license or develop internally alternative
technologies. There can be no assurance that the Company would be able to
license alternative technologies on
-19-
<PAGE>
commercially reasonable terms, or at all, or that the Company would be
capable of developing internally such technologies. Furthermore, there can be
no assurance that other companies may not independently develop technology
with functionality similar or superior to the FLARe technology that does not
or is claimed not to infringe the FLARe patents, or that otherwise
circumvents the technology licensed to the Company.
The Company is aware of third party patents that contain issued claims that
may cover certain aspects of the Company's reagent technologies. There can be no
assurance that the Company would not be required to license any such patents to
produce certain reagents, assay kits and related products or that such licenses
would be available on commercially reasonable terms, if at all. Any action
against the Company claiming damages and seeking to enjoin commercial activities
relating to the affected technologies could subject the Company to potential
liability for damages. The Company could incur substantial costs in defending
patent infringement claims, obtaining patent licenses, engaging in interference
and opposition proceedings or other challenges to its patent rights or
intellectual property rights made by third parties, or in bringing such
proceedings or enforcing any patent rights against third parties. The Company's
inability to obtain necessary licenses or its involvement in proceedings
concerning patent rights could have a material adverse effect on the business,
financial condition and results of operations of the Company.
The patent positions of bioanalytical product companies, including the
Company, are uncertain and involve complex legal and factual questions. In
addition, the coverage claimed in a patent application can be significantly
reduced before the patent is issued. Consequently, there can be no assurance
that the patent applications of the Company or its licensor will result in
patents being issued or that any issued patents will provide protection against
competitive technologies or will be held valid if challenged or circumvented.
Others may independently develop products similar to those of the Company or
design around or otherwise circumvent patents issued to the Company. In the
event that any relevant claims of third-party patents are upheld as valid and
enforceable, the Company could be prevented from practicing the subject matter
claimed in such patents, or would be required to obtain licenses from the patent
owners of each of such patents or to redesign its products or processes to avoid
infringement. There can be no assurance that such licenses would be available
or, if available, would be on terms acceptable to the Company or that the
Company would be successful in any attempt to redesign its products or processes
to avoid infringement. If the Company does not obtain necessary licenses, it
could be subject to litigation and encounter delays in product introductions
while it attempts to design around such patents. Alternatively, the development,
manufacture or sale of such products could be prevented. Litigation would result
in significant cost to the Company as well as diversion of management time.
Adverse determinations in any such proceedings could have a material adverse
effect on the Company's business, financial condition and results of operations.
The Company also relies on trade secret and copyright law, and employee and
third-party nondisclosure agreements to protect its intellectual property rights
in its products and technology. There can be no assurance that these agreements
and measures will provide meaningful protection of the Company's trade secrets,
copyrights, know-how, or
-20-
<PAGE>
other proprietary information in the event of any unauthorized use,
misappropriation or disclosure or that others will not independently develop
substantially equivalent proprietary technologies. Litigation to protect the
Company's trade secrets or copyrights would result in significant cost to the
Company as well as diversion of management time. Adverse determinations in
any such proceedings or unauthorized disclosure of the Company's trade
secrets could have a material adverse effect on the Company's business,
financial condition and results of operations. In addition, the laws of
certain foreign countries do not protect the Company's intellectual property
rights to the same extent as do the laws of the United States. There can be
no assurance that the Company will be able to protect its intellectual
property in these markets.
GOVERNMENT REGULATION
While the Company believes that none of the Company's HTS products will be
regulated as medical devices or otherwise subject to FDA regulation, the
Company's clinical diagnostics products, including Luminometer, Q2000, Horizon
and a microplate heater, are subject to FDA regulation as medical devices, as
well as similar foreign regulation. The process of obtaining and maintaining
required regulatory clearances and approvals and otherwise remaining in
regulatory compliance in the United States and certain other countries is
lengthy, expensive and uncertain. Although the Company has phased out production
of Luminometer, Q2000 and the microplate heater, the Company will continue to
manufacture Horizon on an OEM basis. Horizon is used in research and clinical
laboratories to perform IN VITRO diagnostic ("IVD") tests, which are exempt from
investigational device exemption ("IDE") requirements, including the need to
obtain the FDA's prior approval, provided that, among other things, the testing
is noninvasive, the product is not used as a diagnostic procedure without
confirmation by another medically established test or procedure, and
distribution controls are established to assure that IVDs distributed for
research are used only for those purposes. To the Company's knowledge, its OEM
customers have met these conditions. There can be no assurance that the FDA
would agree that the OEM customers' distribution of the Company's clinical
diagnostic products meet and have met the requirements for IDE exemption.
Failure by the Company, its OEM customers or the recipients of the Company's
clinical diagnostic products to comply with the IDE exemption requirements could
result in enforcement action by the FDA, which could adversely affect the
Company's or its OEM customers' ability to gain marketing clearance or approval
of these products or could result in the recall of previously distributed
products.
Applicable law requires that LJL comply with the FDA's current GMP
regulations for the manufacture of its clinical diagnostics products, Q2000,
Luminometer, Horizon and the microplate heater. The FDA monitors compliance with
its GMP regulations by subjecting medical product manufacturers to periodic FDA
inspections of their manufacturing facilities. The FDA has recently revised the
GMP regulations. The new Quality System Regulation imposes design controls and
makes other significant changes in the requirements applicable to manufacturers.
LJL is also subject to other regulatory requirements, and may need to submit
reports to the FDA including adverse event reporting. Failure to comply with GMP
regulations or other applicable legal requirements can lead to, among other
things, warning letters, seizure of violative
-21-
<PAGE>
products, suspension of manufacturing, government injunctions and potential
civil or criminal liability on the part of the Company and the responsible
officers and employees. In addition, the government may halt or restrict
continued sale of such instruments. Any such actions could have a material,
adverse effect on the business, financial condition and results of operations
of the Company.
In order to export its clinical diagnostics instruments, the Company
maintains International Organization for Standardization ("ISO") 9001
certification and applies the CE mark to certain products that are exported,
which subjects LJL's operations to periodic surveillance audits. While the
Company believes it is currently in compliance with GMP regulations and ISO
standards, there can be no assurance that the Company's operations will be found
to comply with GMP regulations, ISO standards or other applicable legal
requirements in the future or that the Company will not be required to incur
substantial costs to maintain its compliance with existing or future
manufacturing regulations, standards or other requirements. Any such
noncompliance or increased cost of compliance could have a material adverse
effect on the Company's business, results of operations and financial condition.
LJL also is subject to numerous federal, state and local laws relating to
safe working conditions, manufacturing practices, environmental protection,
storage, use and disposal of hazardous or potentially hazardous substances. Any
material failure to comply with such laws could require the Company to incur
significant costs and would have a material, adverse effect upon the Company's
ability to do business. Changes in existing requirements or adoption of new
requirements or policies relating to government regulations could materially and
adversely affect the ability of LJL to comply with such requirements.
FUTURE FLUCTUATIONS IN OPERATING RESULTS
The Company's future operating results are likely to fluctuate
substantially from quarter to quarter. The degree of fluctuation will depend on
a number of factors, including the timing and level of sales, the mix of
products sold through direct sales channels and third party distributors, and
any change in the product mix among the Company's planned product lines. Such
fluctuations could have a material adverse effect on its business, financial
condition and results of operations. Because a significant portion of the
Company's business is expected to be derived from orders placed by a limited
number of large customers, variations in the timing of such orders could cause
significant fluctuations in the Company's operating results. Other factors that
may result in fluctuations in operating results include industry acceptance of
HTS as a drug discovery tool, market acceptance of the Company's products, the
timing of new product announcements and the introduction of new products and new
technologies by the Company or its competitors, delays in research and
development of new products, increased research and development expenses,
increased marketing and sales expenses associated with the implementation of the
Company's direct marketing of its products, availability and cost of component
parts from its suppliers, competitive pricing pressures, and developments with
respect to regulatory matters. In connection with future
-22-
<PAGE>
introductions of new products, the Company may be required to establish or
increase reserves or record charges for inventory obsolescence in connection
with unsold inventory, if any, of older generations of products.
The Company's expenditures for research and development, selling and
marketing, and general and administrative functions are based in part on future
revenue projections. The Company may be unable to adjust spending in a timely
manner in response to any unanticipated declines in revenues, which may have a
material adverse effect on the Company's business, financial condition and
results of operations. The Company may be required to reduce prices in response
to competitive pressures or other factors or increase spending to pursue new
market opportunities. Any decline in average selling prices of a product which
is not offset by a reduction in product costs or by sales of other products with
higher gross margins would decrease the Company's overall gross profit and
adversely affect the Company's business, financial condition and results of
operations. In addition, the Company's operating results may vary from the
expectations of public market analysts and investors, and, as a result, the
price of the Common Stock would be materially and adversely affected.
-23-
<PAGE>
PART II. OTHER INFORMATION
<TABLE>
<S> <C>
Item 1: Legal Proceedings
The Company is not currently involved in any material legal proceedings.
Item 2. Changes in Securities and Use of Proceeds
</TABLE>
In connection with its initial public offering in 1998, the
Company filed a Registration Statement on Form S-1, SEC File No.
333-43529 (the "REGISTRATION STATEMENT"), which was declared effective
by the Commission on March 12, 1998. Pursuant to the Registration
Statement, the Company registered 2,300,000 shares of its Common
Stock, $0.001 par value per share, for its own account, of which
2,000,000 shares were sold in the Company's initial public offering
and an additional 88,000 shares were sold in April 1998 when the
underwriters exercised their over-allotment option. The offering
commenced on March 13, 1998 and did not terminate until the 2,088,000
shares had been sold. The aggregate offering price of the registered
shares was $16,100,000 and the aggregate offering price of the amount
sold was $14,616,000. The managing underwriters of the offering were
NationsBanc Montgomery Securities LLC, Hambrecht & Quist LLC, and
Volpe Brown Whelan & Company LLC.
From March 12, 1998 to March 31, 1998, the Company incurred the
following expenses in connection with the offering:
<TABLE>
<S> <C>
Underwriting discounts and commissions $ 784,000
Other expenses 973,600
----------
Total Expenses $1,757,600
</TABLE>
All of such expenses were direct or indirect payments to others.
The net offering proceeds to the Company through March 31, 1998,
after deducting the total expenses above were $12,242,400. From March
12, 1998 to March 31, 1998, the Company used such net offering
proceeds, in direct or indirect payments to others, as follows:
<TABLE>
<S> <C>
Manufacturing, sales, marketing and administrative
infrastructure $ 116,000
Research and development activities 233,000
Repayment of indebtedness 86,000
Purchase and installation of machinery and equipment 22,000
Temporary investments (short-term, investment grade,
interest-bearing financial instruments) 6,978,000
-----------
Total $ 7,435,000
</TABLE>
Each of these amounts is a reasonable estimate of the application
of the net offering proceeds. This use of proceeds does not represent
a material change in the use of proceeds described in the prospectus
of the Registration Statement.
Item 3. Defaults Upon Senior Securities
Not applicable
-24-
<PAGE>
Item 4. Submission of Matters to a Vote of Securities Holders
Not applicable
Item 5. Other Information
Not applicable
Item 6. Exhibits and Reports on Form 8-K
a: Exhibits
Exhibit 10.11 Lease between Company and Coptech West
Exhibit 27.1 - Financial Data Schedule
b: Reports on Form 8-K - There were no reports on Form 8-K filed
during the quarter ended March 31, 1998.
-25-
<PAGE>
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE
REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE
UNDERSIGNED THEREUNTO DULY AUTHORIZED.
LJL BIOSYSTEMS, INC.
DATE: MAY 13, 1998 BY: /S/ ROBERT T. BEGGS
----------------------------
ROBERT T. BEGGS, VICE PRESIDENT OF
FINANCE AND ADMINISTRATION (DULY
AUTHORIZED AND PRINCIPAL FINANCIAL
AND ACCOUNTING OFFICER)
-26-
<PAGE>
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT PAGE
------- ----
<S> <C> <C>
10.11 Lease between Company and Coptech West . . . . . . . . 28
27.1 Financial Data Schedule . . . . . . . . . . . . . . . 56
-27-
</TABLE>
<PAGE>
STANDARD SUBLEASE
AMERICAN INDUSTRIAL REAL ESTATE ASSOCIATION
AIR
1. PARTIES. This Sublease, dated, for reference purposes only, March 26
1998, is made by and between Coptech West, a California Corporation (herein
called "Sublessor") and LJL Biosystems (herein called "Sublessee").
2. PREMISES. Sublessor hereby subleases to Sublessee and Sublessee
hereby subleases from Sublessor for the term, at Santa Clara State of
California, commonly known as 405 Tasman Drive, Sunnyvale, California and
described as approximately 9,600 square feet of R&D space of a larger 28,350
square foot R&D building. Said real property including the land and all
improvements thereon, is hereinafter called the "Premises".
3. TERM.
3.1 TERM. The term of this Sublease shall be for + or - twelve (12)
months commencing on **May 1, 1998 and ending on May 31, 1999 unless sooner
terminated pursuant to any provision hereof.
4. RENT. Sublessee shall pay to Sublessor as rent for the Premises equal
monthly payments of $16,800.00, in advance, on the first (1st) day of each
month of the term hereof. Sublessee shall pay Sublessor prior to May 1, 1998
$16,800.00 as rent for the time period of May 1, 1998 through May 31, 1998
** SEE PARAGRAPH #13
Rent for any period during the term hereof which is for less than one (1) month
shall be a prorata portion of the monthly installment. Rent shall be payable
in lawful money of the United States to Sublessor at the address stated herein
or to such other persons or at such other places as Sublessor may designate in
writing.
5. SECURITY DEPOSIT. Sublessee shall deposit with Sublessor upon execution
hereof $ 16,800.00 as security for Sublessee's faithful performance of
Sublessee's obligations hereunder. If Sublessee fails to pay rent or other
charges due hereunder, or otherwise defaults with respect to any provision of
this Sublease, Sublessor may use, apply or retain all or any portion of said
deposit for the payment of any rent or other charge in default or for the
payment of any other sum to which Sublessor may become obligated by reason of
Sublessee's default, or to compensate Sublessor for any loss or damage which
Sublessor may suffer thereby. If Sublessor so uses or applies all or any
portion of said deposit, Sublessee shall within ten (10) days after written
demand therefore deposit cash with Sublessor in an amount sufficient to restore
said deposit to the full amount hereinabove stated and Sublessee's failure to do
so shall be a material breach of this Sublease. Sublessor shall not be required
to keep said deposit separate from its general accounts. Said deposit, or so
much thereof as has not theretofore been applied by Sublessor, shall be
returned, without payment of interest or other increment for its use to
Sublessee (or at Sublessor's option, to the last assignee, if any, of
Sublessee's interest hereunder) at the expiration of the term hereof, and after
Sublessee has vacated the Premises. No trust relationship is created herein
between Sublessor and Sublessee with respect to said Security Deposit.
6. USE.
6.1 USE. The Premises shall be used and occupied only for office,
research and development, light manufacturing/warehouse activities and any
other legally related use and for no other purpose.
6.2 COMPLIANCE WITH LAW.
(a) Except as provided in paragraph 6.2(a), Sublessee shall, at
Sublessee's expense, comply promptly with all applicable statutes, ordinances,
rules, regulations, orders, restrictions of record, and requirements in effect
during the term or any part of the term hereof regulating the use by Sublessee
of the Premises. Sublessee
Page 28
<PAGE>
shall not use or permit the use of the Premises in any manner that will tend
to create waste or a nuisance or, if there shall be more than one tenant of
the building containing the Premises, which shall tend to disturb such other
tenants.
6.3 CONDITION OF PREMISES. Except as provided in paragraph
6.2(a), Sublessee hereby accepts the Premises in their condition existing as
of the date of the execution hereof. Sublessee acknowledges that neither
Sublessor nor Sublessor's agents have made any representation or warranty as
to the suitability of the Premises for the conduct of Sublessee's business.
7. MASTER LEASE.
7.1 Sublessor is the Lessee of the Premises by virtue of a lease,
hereinafter referred to as the "Master Lease", a copy of which is attached
hereto marked Exhibit 1, dated May , 1997, wherein Berg And Berg
Enterprises, Inc., a California Corporation
is the Lessor, hereinafter referred to as the "Master Lessor".
7.2 This Sublease is and shall be at all times subject and subordinate
to the Master Lease.
7.3 The terms, conditions and respective obligations of Sublessor and
Sublessee to each other under this Sublease shall be the terms and conditions of
the Master Lease except for those provisions of the Master Lease which are
directly contradicted by this Sublease in which event the terms of this Sublease
document shall control over the Master Lease. Therefore, for the purposes of
this Sublease, wherever in the Master Lease the word "Lessor" is used it shall
be deemed to mean the Sublessor herein and wherever in the Master Lease the word
"Lessee" is used it shall be deemed to mean the Sublessee herein.
7.4 During the term of this Sublease and for all periods subsequent
for obligations which have arisen prior to the termination of this Sublease,
Sublessee does hereby expressly assume and agree to perform and comply with, for
the benefit of Sublessor and Master Lessor, each and every obligation of
Sublessor under the Master Lease except for the following paragraphs which are
excluded therefrom: Term, Rent, Security Deposit, 1.1, 2.1, 20, 25,
34, 35 A & B, 33.5
7.5 The obligations that Sublessee has agreed to perform under
paragraph 7.4 hereof are hereinafter referred to as the "Sublessee's Assumed
Obligations". The obligations that Sublessee has not agreed to perform under
paragraph 7.4 hereof are hereinafter referred to as the "Sublessor's Remaining
Obligations".
7.6 Sublessee shall hold Sublessor free and harmless of and from all
liability, judgments, costs, damages, claims or demands, including reasonable
attorney's fees, arising out of Sublessee's failure to comply with or perform
Sublessee's Assumed Obligations.
7.7 Sublessor agrees to maintain the Master Lease during the entire
term of this Sublease, subject, however, to any earlier termination of the
Master Lease without the fault of the Sublessor, and to comply with or perform
Sublessor's Remaining Obligations and to hold Sublessee free and harmless of and
from all liability, judgments, costs, damages, claims or demands arising out of
Sublessor's failure to comply with or perform Sublessor's Remaining Obligations.
7.8 Sublessor represents to Sublessee that the Master Lease is in full
force and effect and that no default exists on the part of any party to the
Master Lease.
8. ASSIGNMENT OF SUBLEASE AND DEFAULT.
8.1 Sublessor hereby assigns and transfers to Master Lessor the
Sublessor's interest in this Sublease and all rentals and income arising
therefrom, subject however to terms of Paragraph 8.2 hereof.
8.2 Master Lessor, by executing this document, agrees that until a
default shall occur in the performance of Sublessor's Obligations under the
Master Lease, that Sublessor may receive, collect and enjoy the rents accruing
under this Sublease. However, if Sublessor shall default in the performance of
its obligations to Master Lessor then Master Lessor may, at its option, receive
and collect, directly from Sublessee, all rent owing and to be owed under this
Sublease. Master Lessor shall not, by reason of this assignment of the Sublease
nor by reason of the collection of the rents from the Sublessee, be deemed
liable to Sublessee for any failure of the Sublessor to perform and comply with
Sublessor's Remaining Obligations.
8.3 Sublessor hereby irrevocably authorizes and directs Sublessee,
upon receipt of any written notice from the Master Lessor stating that a default
exists in the performance of Sublessor's obligations under the Master Lease, to
pay to Master Lessor the rents due and to become due under the Sublease.
Sublessor agrees that Sublessee shall have the right to rely upon any such
statement and request from Master Lessor, and that Sublessee shall pay such
rents to Master Lessor without any obligation or right to inquire as to whether
such default exists and notwithstanding any notice from or claim from Sublessor
to the contrary and Sublessor shall have no right or claim against Sublessee for
any such rents so paid by Sublessee.
8.4 No changes or modifications shall be made to this Sublease without
the consent of Master Lessor.
Page 29
<PAGE>
9. CONSENT OF MASTER LESSOR.
9.1 In the event that the Master Lease requires that Sublessor obtain
the consent of Master Lessor to any subletting by Sublessor then, this Sublease
shall not be effective unless, within ten (10) days of the date hereof, Master
Lessor signs this Sublease thereby giving its consent to this Subletting.
9.2 In the event that the obligations of the Sublessor under the
Master Lease have been guaranteed by third parties then this Sublease, nor the
Master Lessor's consent, shall not be effective unless, within ten (10) days of
the date hereof, said guarantors sign this Sublease hereby giving guarantors
consent to this Sublease and the terms thereof.
9.3 In the event that Master Lessor does give such consent then:
(a) Such consent will not release Sublessor of its obligations
or alter the primary liability of Sublessor to pay the rent and perform and
comply with all of the obligations of Sublessor to be performed under the Master
Lease.
(b) The acceptance of rent by Master Lessor from Sublessee or
any one else liable under the Master Lease shall not be deemed a waiver by
Master Lessor of any provisions of the Master Lease.
(c) The consent to this Sublease shall not constitute a consent
to any subsequent subletting or assignment.
(d) In the event of any default of Sublessor under the Master
Lease, Master Lessor may proceed directly against Sublessor, any guarantors or
any one else liable under the Master Lease or this Sublease without first
exhausting Master Lessor's remedies against any other person or entity liable
thereon to Master Lessor.
(e) Master Lessor may consent to subsequent sublettings and
assignments of the Master Lease or this Sublease or any amendments or
modifications thereto without notifying Sublessor nor any one else liable under
the Master Lease and without obtaining their consent and such action shall not
relieve such persons from liability.
(f) In the event that Sublessor shall default in its obligations
under the Master Lease, then Master Lessor, at its option and without being
obligated to do so, may require Sublessee to attorn to Master Lessor in which
event Master Lessor shall undertake the obligations of Sublessor under this
Sublease from the time of the exercise of said option to termination of this
Sublease but Master Lessor shall not be liable for any prepaid rents nor any
security deposit paid by Sublessee unless received, nor shall Master Lessor be
liable for any other defaults of the Sublessor under the Sublease.
9.4 The signatures of the Master Lessor and any Guarantors of
Sublessor at the end of this document shall constitute their consent to the
terms of this Sublease.
9.5 Master Lessor acknowledges that, to the best of Master Lessor's
knowledge, no default presently exists under the Master Lease of obligations to
be performed by Sublessor and that the Master Lease is in full force and effect.
9.6 In the event that Sublessor defaults under its obligations to be
performed under the Master Lease by Sublessor, Master Lessor agrees to deliver
to Sublessee a copy of any such notice of default. Sublessee shall have the
right to cure any default of Sublessor described in any notice of default within
ten (10) days after service of such notice of default on Sublessee. If such
default is cured by Sublessee then Sublessee shall have the right of
reimbursement and offset from and against Sublessor.
10. BROKERS FEE.
10.1 Upon execution hereof by all parties, Sublessor shall pay to Bishop
Hawk, Inc., a licensed real estate broker, (herein called "Broker"), a
fee as set forth in a separate agreement between Sublessor and Broker, or in the
event there is no separate agreement between Sublessor and Broker, the sum of
$ 12,096.00 (**) for brokerage services rendered by Broker to Sublessor
in this transaction. Said fee shall be split 50/50 between Bishop Hawk, inc.
and Wayne Mascia Associates. If Tenant exercises option for an additional eight
(8) months, an additional fee of $8,064.00 shall be due and payable to Bishop
Hawk, Inc. Said additional fee shall also be split 50/50 between Bishop Hawk,
Inc. and Wayne Mascia Associates. (**) SAID FEE WILL BE ADJUSTED TO CORRECTLY
PORTRAY THE EXACT OCCUPANCY DATE.
11. ATTORNEY'S FEES. If any party or the Broker named herein brings an
action to enforce the terms hereof or to declare rights hereunder, the
prevailing party in any such action, on trial and appeal, shall be entitled to
his reasonable attorney's fees to be paid by the losing party as fixed by the
Court. The provision of this paragraph shall inure to the benefit of the Broker
named herein who seeks to enforce a right hereunder.
ADDITIONAL PROVISIONS. (If there are no additional provisions draw a line from
this point to the next printed word after the space left here. If there are
additional provisions place the same here).
Page 30
<PAGE>
13. Coptech intends to provide the space May 1, 1998. If the space is not
deliverable, Tenant shall not be obligated to pay until deliverability occurs.
Rate shall be prorated on a daily basis (taking monthly rent and dividing by the
number of days in that month). In no event shall the commencement date be later
than May 31, 1998.
14. SUBLESSEE'S RIGHT TO EXTEND. Sublessee shall have the right to extend
said Sublease for eight (8) months with sixty (60) day written notice. All
terms and conditions of Sublease shall remain in full force and effect during
any extension.
15. The CAC charges shall be handled as per the Master Lease. The charges
for CAC shall be paid on a pro-rata basis. The estimated CAC shall be 9,600 sq.
ft. / 28,350 sq. ft. = (33.86%) x 3,821 = $1,294. In addition to CAC charges,
Sublessee shall pay their pro-rata share of the HVAC maintenance for the
building. HVAC has been set up to be handled outside the CAC charges.
IF THIS SUBLEASE HAS BEEN FILLED IN IT HAS BEEN PREPARED FOR
SUBMISSION TO YOUR ATTORNEY FOR HIS APPROVAL. NO REPRESENTATION
OR RECOMMENDATION IS MADE BY THE REAL ESTATE BROKER OR ITS AGENTS
OR EMPLOYEES AS TO THE LEGAL SUFFICIENCY, LEGAL EFFECT, OR TAX
CONSEQUENCES OF THIS sUBLEASE OR THE TRANSACTION RELATING THERETO.
Executed at Sunnyvale, CA Coptech West
------------- ------------
on March 30, 1998 By: /s/ Dan Lonaric, CFO
-------------- -----------------------
Address: 1190 MORSE AVENUE
-----------------
Executed at Sunnyvale, CA LJL Biosystems
------------- --------------
on March 30, 1998 By: /s/ Galina Leytes
-------------- -------------------
Address: 404 Tasman Drive
----------------
Page 31
<PAGE>
FIRST ADDENDUM TO SUBLEASE
This First Addendum to Sublease (this "Addendum") is made by and between
Coptech West, a California corporation as sublessor ("Sublessor"), and LJL
Biosystems as sublessee ("Sublessee"), to be a part of that certain Sublease of
even date herewith between Sublessor and Sublessee (the "Sublease"). Sublessor
and Sublessee agree that, notwithstanding anything to the contrary in the
Sublease, the Sublease is hereby modified and supplemented as set forth below.
1. TERM. The Sublease term shall commence (the "Commencement Date")
on the later of May 1, 1998, and the date on which Sublessor delivers legal
possession of the Premises to Sublessee in broom clean, and otherwise in the
same condition as of the date hereof, with all approvals and permits from the
appropriate governmental authorities required for the legal occupancy of the
Premises. If the Commencement Date has not occurred for any reason before
June 1, 1998, then, in addition to Sublessee's other rights and remedies,
Sublessee may terminate the Sublease by written notice to Sublessor,
whereupon any monies paid by Sublessee to Sublessor shall be reimbursed.
2. CONDITION OF PREMISES. Sublessor hereby represents that as of the
Commencement Date, to the best of Sublessor's knowledge, (a) the Premises are
in good condition, (b) the Premises do not violate any applicable building
code regulation or ordinance and (c) the heating, ventilating and air
conditioning systems serving the Premises are in good condition, working
order and repair. Sublessee's acceptance of the Premises shall not be deemed
a waiver of the above representations.
3. SIGNAGE: Sublessee shall be allowed to place three (3) signs on
the exterior of the Premises. The signs must conform to all applicable codes
and ordinances and be approved by Sublessor (as to size, color, placement,
style, etc.) in the exercise of its reasonable discretion.
4. INSURANCE AND INDEMNIFICATION. Sublessor shall not be released or
indemnified from any damages, liabilities, judgments, actions, claims,
attorneys' fees, consultants' fees, payments, costs or expenses arising from
the negligence or willful misconduct of Sublessor or its agents, contractors,
licensees or invitees, Sublessor's violation of laws or a breach of
Sublessor's obligations or representations under the Sublease.
Notwithstanding anything to the contrary in the Sublease or the Master Lease,
in no event shall Sublessor be required to keep in force a standard policy of
commercial general liability insurance and a property damage policy having a
combined single limit in excess of one million dollars ($1,000,000.00).
5. WAIVER OF SUBROGATION. The parties hereto, including Master
Landlord by reason of its consent hereto, release each other and their
respective agents, employees, successors and assigns from all liability for
damage to any property that is caused by or results from a risk which is
actually insured against or which would normally be covered by the standard
form of "all risk" property insurance, without regard to the negligence or
willful misconduct of the entity so released. Each party shall use its best
efforts to cause each insurance policy it obtains to provide that the insurer
thereunder waives all right of recovery by way of subrogation as required
herein in connection with any damage covered by the policy.
6. ASSIGNMENT AND SUBLETTING. Sublessee shall not assign this
Sublease or sublease the Subleased Premises without Sublessor and Master
Lessor's consent, which consent shall not be unreasonably withheld.
Sublessee, without Sublessor's or Master Landlord's prior written consent,
may sublet the Premises or assign the Sublease to: (a) a corporation
controlling, controlled by or under common control with Sublessee; (b) a
corporation related to Sublessee by merger, consolidation or non-bankruptcy
reorganization; or (c) a purchaser of substantially all of Sublessee's
assets. A sale of Sublessee's capital stock shall not be deemed an
assignment, subletting or other transfer of the Sublease or the Premises.
Page 32
<PAGE>
7. RENTAL ADJUSTMENTS. In no event shall Sublessee's obligation to
pay Basic Operating Costs exceed the amount of Basic Operating Costs due and
payable by Sublessor under the Master Lease. Sublessee shall pay Sublessee's
share of such expenses as and when the same are due and payable to Master
Landlord under the Master Lease. Sublessee shall be entitled to its pro rata
share of all credits, if any, given by Master Landlord to Sublessor for
Sublessor's overpayment of such expenses. Notwithstanding anything to the
contrary in the Sublease, Sublessee shall not be required to pay any
additional rent or perform any obligation that is (i) fairly allocable to any
period of time prior to the commencement date of the Sublease or following
the expiration or sooner termination of the Sublease or (ii) payable as a
result of a default by Sublessor of any of its obligations under the Master
Lease. In addition to base rent and part of the expenses is the contract for
HVAC maintenance and repair which costs Sublessor $1,100.00 per month.
Sublessee's prorated share shall be $382.62 per month.
8. DAMAGE BY FIRE, ETC.. If the Premises are damaged by any peril,
Sublessee shall have the option to terminate the Sublease upon written notice
to the Sublessor if the Premises cannot be, or are not in fact, fully
restored by Master Landlord to their prior condition within one hundred
twenty (120) days after the damage.
9. SURRENDER OF PREMISES. In no event shall Sublessee's obligation
to surrender the Premises require Sublessee to repair or restore the Premises
to a condition better than the condition in which the Premises existed as of
the commencement date of the Sublease and Sublessee shall only be responsible
for repairing or restoring those elements of the Premises damaged during the
Sublease Term. Additionally, Sublessee shall not be required to remove at
the expiration of the Sublease term or otherwise, alterations or improvements
to the Premises made by or for the account of Sublessor.
10. TAXES PAYABLE BY SUBLESSEE. Sublessee shall have no obligation
to pay for any taxes levied or assessed on (i) the value of any leasehold
improvements, alterations or additions made by or for the account of
Sublessor or (ii) the value of Sublessor's personal property located on the
Premises.
11. SUBLESSOR'S OBLIGATIONS. Sublessor shall not, without Sublessee's
prior written consent, terminate the Master Lease, commit any acts that would
entitle Master Landlord to terminate the Master Lease, or amend or waive any
provisions of the Master Lease or make any elections, exercise any right or
remedy or give any consent or approval under the Master Lease. Sublessor,
with respect to the obligations of Master Landlord under the Master Lease,
shall use Sublessor's diligent good faith efforts to cause Master Landlord to
perform such obligations for the benefit of Sublessee.
12 QUIET ENJOYMENT. Sublessee shall peacefully have, hold and enjoy
the Premises, subject to the terms and conditions of the Sublease, provided
that there is not an event of default by Sublessee. Sublessor shall fully
perform all of its obligations under the Master Lease to the extent Sublessee
has not expressly agreed to perform such obligations under the Sublease. In
the event, however, that Sublessor defaults in the performance or observance
of any of Sublessor's remaining obligations under the Master Lease or fails
to perform Sublessor's stated obligations under the Sublease or to enforce,
for Sublessee's benefit, Master Landlord's obligations under the Master
Lease, then Sublessee shall give Sublessor notice specifying in what manner
Sublessor has defaulted, and if such default shall not be cured by Sublessor
within thirty (30) days thereafter (except that if such default cannot be
cured within said thirty (30) day period, this period shall be extended for
an additional reasonable time, provided that Sublessor commences to cure such
default within such thirty (30) day period and proceeds diligently thereafter
to effect such cure as quickly as possible), then Sublessee shall be entitled
to cure such default and promptly collect from Sublessor, Sublessee's
reasonable expenses in so doing (including, without limitation, reasonable
attorneys' fees and court costs).
13. ASSIGNMENT OF RIGHTS. Sublessor hereby assigns to Sublessee all
warranties given and indemnities made by Master Landlord to Sublessor under
the Master Lease which would reduce Sublessee's obligations hereunder, and
shall cooperate with Sublessee to enforce all such warranties and indemnities.
14. NOTICE. All notices and demands sent by United States Mail shall
be deemed delivered three (3) business days after mailing.
Page 33
<PAGE>
15. APPROVALS. Whenever the Sublease requires an approval, consent,
designation, determination, selection or judgment by either Sublessor or
Sublessee, such approval, consent, designation, determination, selection or
judgment and any conditions imposed thereby shall be reasonable and shall not
be unreasonably withheld or delayed and, in exercising any right or remedy
hereunder, each party shall at all times act reasonably and in good faith.
16. EFFECT OF ADDENDUM. All terms with initial capital letters used
herein as defined terms shall have the meanings ascribed to them in the
Sublease unless specifically defined herein.
In witness whereof, said parties hereunto subscribe their names.
Sublessor: Sublessee:
COPTECH WEST LJL BIOSYSTEMS
By /s/ Dan Lonaric By /s/ Robert T. Beggs
---------------- ---------------------
Name Dan Loncaric Name Robert T. Beggs
-------------- --------------------
Title Chief Financial Officer Title Vice President, Finance &
----------------------- -------------------------
Administration
--------------
Dated April 2, 1998 Dated April 2, 1998
------------- -------------
Page 34
<PAGE>
CONSENT OF MASTER LESSOR
Notwithstanding any of the provisions in the attached sublease dated March
26, 1998 or the first Addendum thereto (collectively, the "Sublease") between
Coptech West, a California corporation ("Sublessor"), and LJL Biosystems, a
Delaware corporation ("Sublessor"), Berg & Berg Enterprises, Inc. ("Master
Lessor"), a California corporation, hereby consents to the Sublease on the
following terms and conditions:
1. Nothing contained in the Sublease or this consent shall create any
obligations or duties on the part of Master Lessor beyond those set forth in the
Standard Form Lease (the "Master Lease") dated May 8, 1997 by and between Master
Leasor and Sublessor.
2. Nothing in the Sublease or this consent shall in any manner amend, alter,
or modify any provision of the Master Lease or otherwise affect Master Lessor's
rights and remedies under the Master Lease. The Master Lease shall remain in
full force and effect.
3. This consent applies only to the Sublease and shall not authorize any
further sublease or assignment during the term of the Master Lease or during any
option period of the Master Lease. Master Lessor may consent to subsequent
sublettings or assignments under the Master Lease or the Sublease or
modifications or amendments thereto without notifying or obtaining the consent
of Sublessor or anyone else liable under the Master Lease and such action shall
not relieve such persons from liability.
4. Termination of the Master Lease for any reason shall cause an automatic
termination of the Sublease.
5. The acceptance of rent by Master Lessor from Sublessee shall not be deemed
a waiver by Master Lessor of any provision of the Master Lease.
6. Sublessor shall remain primarily liable for the performance of all
conditions, covenants, and obligations of "Lessee" under the Master Lease and in
the event of a default under the Master Lease, Master Lessor may proceed
directly against Sublessor, any guarantor, or anyone else liable under the
Master Lease without the necessity of exhausting remedies against Sublessee or
any other person or entity liable thereon.
MASTER LESSOR
/s/ Carl E. Berg Dated: April 14, 1998
- ----------------- --------------
By: Carl E. Berg President
For Berg & Berg Enterprises, Inc.
SUBLESSOR
Coptech West
By: /s/ Dan Loncaric Dated: April 14, 1998
----------------- --------------
Its: Chief Financial Officer
------------------------
SUBLESEE
LJL Biosystems
By: /s/ Galina Leytes Dated: April 14, 1998
------------------- --------------
Its: Executive Vice President
------------------------
Page 35
<PAGE>
MASTER LEASE BETWEEN COPTECH WEST AND BERG & BERG
PARTIES: This Lease, executed in duplicate at Cupertino, California, on May 8th,
1997, by and between Berg & Berg Enterprises, Inc., a California Corporation,
and Coptec West, a California Corporation, hereinafter called respectively
Lessor and Lessee, without regard to number or gender.
USE: WITNESSETH: That Lessor hereby leases to Lessee, and Lessee hires from
Lessor, for the purpose of conducting therein office, research and development,
light manufacturing, and warehouse activities, and any other legal activity; and
for no other purpose without obtaining the prior written consent of Lessor.
PREMISES: The real property with appurtenances as shown on Exhibit A (the
"Premises") situated in the City of San Jose, County of Santa Clara, State of
California, and more particularly described as follows:
The Premises includes 28,350 square feet of building, including all
improvements thereto, as shown on Exhibit A including the right to
use up to 99 unreserved parking spaces. The addresses for the
Premises are 1190 Morse and 405 Tasman Drive, Sunnyvale, California.
Lessee's pro-rata share of the Premises is 100%.
TERM: The term shall be for sixty (60) months unless extended pursuant to
Section 35 of this Lease (the "Lease Term"), commencing on the Commencement Date
as defined in Section 1 and ending sixty (60) months thereafter.
RENT: Base rent shall be payable in monthly installments as follows:
<TABLE>
<CAPTION>
BASE RENT ESTIMATED CAC* TOTAL
--------- -------------- -----
<S> <C> <C> <C>
Months 1 through 12 $25,940 $3,821 $29,761
Months 13 through 24 $27,074 $3,821 $30,895
Months 25 through 36 $27,925 $3,821 $31,746
Months 37 through 48 $29,059 $3,821 $32,880
Months 49 through 60 $30,193 $3,821 $34,014
</TABLE>
* CAC charges to be adjusted per Common Area Charges Section below.
Base rent as scheduled above shall be payable in advance on or before the first
day of each calendar month during the Lease Term. The term "Rent," as used
herein, shall be deemed to be and to mean the base monthly rent and all other
sums required to be paid by Lessee pursuant to the terms of this Lease. Rent
shall be paid in lawful money of the United States of America, without offset or
deduction, and shall be paid to Lessor at such place or places as may be
designated from time to time by Lessor. Rent for any period less than a
calendar month shall be a pro rata portion of the monthly installment. Upon
execution of this Lease, Lessee shall deposit with Lessor the first month's
rent.
SECURITY DEPOSIT: Lessee shall deposit with Lessor the sum of Twenty Nine
Thousand Seven Hundred Sixty-One Dollars ($29,761) (the "Security Deposit").
The Security Deposit shall be held by Lessor as
Page 36
<PAGE>
security for the faithful performance by Lessee of all of the terms,
covenants, and conditions of this Lease applicable to Lessee. If Lessee
commits a default as provided for herein, including but not limited to a
default with respect to the provisions contained herein relating to the
condition of the Premises, Lessor may (but shall not be required to) use,
apply or retain all or any part of the Security Deposit for the payment of
any amount which Lessor may spend by reason of default by Lessee. If any
portion of the Security Deposit is so used or applied, Lessee shall, within
ten days after written demand therefor, deposit cash with Lessor in an amount
sufficient to restore the Security Deposit to its original amount. Lessee's
failure to do so shall be a default by Lessee. Any attempt by Lessee to
transfer or encumber its interest in the Security Deposit shall be null and
void. Upon execution of this Lease, Lessee shall deposit with Lessor the
Security Deposit.
COMMON AREA CHARGES: Lessee shall pay to Lessor, as additional Rent, an amount
equal to Lessee's pro-rate share of the total common area charges of the
Premises as defined below (the common area charges for the Premises is referred
to herein as ("CAC")). Lessee shall pay to Lessor as Rent, on or before the
first day of each calendar month during the Lease Term, subject to adjustment
and reconciliation as provided hereinbelow, the sum of Three Thousand Eight
Hundred Twenty-One Dollars ($3,821), said sum representing Lessee's estimated
monthly payment of Lessee's percentage share of CAC. It is understood and
agreed that Lessee's obligation under this paragraph shall be prorated to
reflect the Commencement Date and the end of the Lease Term. Upon execution of
this Lease, Lessee shall deposit with Lessor the first month's estimated CAC.
Lessee's estimated monthly payment of CAC payable by Lessee during the calendar
year in which the Lease commences is set forth above. At or prior to the
commencement of each succeeding calendar year term (or as soon as practical
thereafter), Lessor shall provide Lessee with Lessee's estimated monthly payment
for CAC which Lessee shall pay to Lessor as Rent. Within 120 days of the end of
the calendar year and the end of the Lease Term, Lessor shall provide Lessee a
statement of actual CAC incurred including capital reserves for the preceding
year or other applicable period in the case of a termination year. If such
statement shows that Lessee has paid less than its actual percentage, then
Lessee shall on demand pay to Lessor the amount of such deficiency. If such
statement shows that Lessee has paid more than its actual percentage, then
Lessor shall, at its option, promptly refund such excess to Lessee or credit the
amount thereof to the Rent next becoming due from Lessee. Lessor reserves the
right to revise any estimate of CAC if the actual or projected CAC show an
increase or decrease in excess of 10% from an earlier estimate for the same
period. In such event, Lessor shall provide a revised estimate to Lessee,
together with an explanation of the reasons therefor, and Lessee shall revise
its monthly payments accordingly. Lessor's and Lessee's obligation with respect
to adjustments at the end of the Lease Term or earlier expiration of this Lease
shall survive the Lease Term or earlier expiration.
As used in this Lease, CAC shall include but is not limited to: (i) items as
specified in Sections 5(b), 6, 16 and 31; (ii) all costs and expenses
including but not limited to supplies, materials, equipment and tools used or
required in connection with the operation and maintenance of the Premises;
(iii) licenses, permits and inspection fees; (iv) all other costs incurred
by Lessor in maintaining and operating the Premises; (v) all reserves for
capital replacements and government regulations imposed on the Premises not
related to Lessee's use and occupancy of the Premises; and (vi) an amount
equal to five percent (5%) of the aggregate of all CAC, as compensation for
Lessor's accounting and processing services. Lessee shall have the right to
review the basis and computation analysis used to derive the CAC applicable
to this Lease annually. Notwithstanding the above, Lessee shall be
responsible, at its sole cost and expenses, for any and
Page 37
<PAGE>
all maintenance, repairs, and replacements for all HVAC system(s), including
but not limited, to any clean room related HVAC systems at the Premises.
LATE CHARGES: Lessee hereby acknowledges that a late payment made by Lessee to
Lessor of Rent and other sums due hereunder will cause Lessor to incur costs not
contemplated by this Lease, the exact amount of which will be extremely
difficult to ascertain. Such costs include, but are not limited to, processing
and accounting charges, and late charges, which may be imposed on Lessor
according to the terms of any mortgage or trust deed covering the Premises.
Accordingly, if any installment of Rent or any other sum due from Lessee is not
received by Lessor or Lessor's designee within ten (10) days after such amount
is due, Lessee shall pay to Lessor a late charge equal to five (5%) percent of
such overdue amount. The parties hereby agree that such late charge represents
a fair and reasonable estimate of the costs Lessor will incur by reason of late
payments made by Lessee. Acceptance of such late charges by Lessor shall in no
event constitute a waiver of Lessee's default with respect to such overdue
amount, nor shall it prevent Lessor from exercising any of the other rights and
remedies granted hereunder.
QUIET ENJOYMENT: Lessor covenants and agrees with Lessee that upon Lessee paying
Rent and performing its covenants and conditions under this Lease, Lessee shall
and may peaceably and quietly have, hold and enjoy the Premises for the Lease
Term, subject, however, to the rights reserved by Lessor hereunder.
IT IS FURTHER MUTUALLY AGREED BETWEEN THE PARTIES AS FOLLOWS:
1. POSSESSION: Possession shall be deemed tendered and the term shall commence
on August 15, 1997 or forty-five (45) days after the existing Lessee vacates the
property, but not prior to July 1, 1997 (the "Commencement Date").
1.1 COMMENCEMENT DATE MEMORANDUM: When the actual Commencement Date is
determined, the parties shall execute a Commencement Date Memorandum setting
forth the Commencement Date, the expiration date of the Lease Term and the
actual square footage of the Premises and any required adjustments to base rent
and CAC, but failure to do so shall not affect the continuing validity and
enforceability of this Lease, which shall remain in full force and effect.
2. ACCEPTANCE OF PREMISES AND COVENANTS TO SURRENDER: Lessee accepts the
Premises in an "AS IS" condition and "AS IS" state of repair, subject to
Lessor's representation that the Premises are in good order and repair, and
comply with all requirements for occupancy as of the Commencement Date. Lessee
agrees on the last day of the Lease Term, or on the sooner termination of this
Lease, to surrender the Premises to Lessor in Good Condition and Repair. Good
Condition and Repair ("Good Condition and Repair") shall not mean original
condition, but shall mean that the Premises are in a commercially acceptable
condition suitable for occupancy by a reasonable lessee. The interior walls of
all office and warehouse areas, the floors of all office and warehouse areas,
all suspended ceilings and any carpeting are to be cleaned and in Good Condition
and Repair. Lessee, on or before the end of the Lease Term or sooner termination
of this Lease, shall remove all its personal property and trade fixtures from
the Premises, and all such property not so removed shall be deemed to be
abandoned by Lessee. Lessee shall reimburse Lessor for all disposition costs
incurred by Lessor relative to Lessee's abandoned property. If the Premises are
not surrendered at the end of the Lease Term or earlier termination of this
Lease, Lessee shall indemnify Lessor against loss or liability resulting from
any delay caused by Lessee in surrendering the Premises including, without
limitation, any claims made by any succeeding Lessee founded on such delay.
Page 38
<PAGE>
2.1 LESSEE'S IMPROVEMENTS: Lessee has advised Lessor that it intends to complete
certain improvements to the Premises which shall be completed at the sole cost
and expense of Lessee. Lessor and Lessee hereby agree that the following terms
and conditions represent the parties mutual understanding and agreement with
respect to Lessee's improvements to the Premises.
1. Lessee shall be responsible for designing, contracting, completing,
and paying for the tenant improvements at the Premises; however, in no
event will the contractor's failure to complete the tenant improvements
on time result in a delay of the Commencement Date or Lessee's
obligation to commence paying Rent.
2. All tenant improvements shall be completed in a good and workmanlike
manner, in compliance with all government codes, requirements, and
regulations, and with all necessary permits. Lessee understands and
acknowledges that the tenant improvements contemplated by Lessee will
force modifications to the Premises to comply with government codes,
requirements, and regulations and Lessee shall be responsible and shall
pay for any such modifications.
3. Lessor shall review and approve all plans for the tenant improvements
to be made to the Premises and Lessor's approval shall not be
unreasonably withheld. If Lessee has not heard back from Lessor within
five (5) business days, then the plans submitted shall be deemed
approved. Time is of the essence.
4. Lessee and its contractors shall not change or affect the structural
components or structural characteristics of the Premises without signed
engineering drawings and specific written approval of Lessor.
5. Lessee shall provide general liability insurance in the amount of not
less than Two Million Dollars ($2,000,000) naming Lessor as an
additional insured prior to starting any work at the Premises and prior
to taking possession of the Premises. Lessor shall cause its general
contractor to provide general liability insurance in the amount of not
less than Five Million Dollars ($5,000,000) naming Lessor as an
additional insured prior to starting any work at the Premises.
6. Lessor will contribute a maximum of $40,000.00 toward the completed
tenant improvements based on the following ratio and terms:
- $120,000 costs, Lessor shall contribute $40,000
- $110,000 costs, Lessor shall contribute $35,000
- $105,000 costs, Lessor shall contribute $30,000
- Less than $105,000 costs, Lessor shall contribute $25,000.00
Lessor's payment is to be made ten (10) days after receipt of final lien
releases and provided all improvements are completed.
7. Lessor shall have no responsibility or liability for: (i) the
Lessee's improvements except for payment as provided in 2.1.6 above,
(ii) for any delay of the Commencement Date, (iii) Lessee's obligation
to commence paying Rent on the Commencement Date, and (iv) claims
asserted by Lessee or Lessee's Agents related to the Lessee's
improvements.
Page 39
<PAGE>
3. USES PROHIBITED: Lessee shall not commit, or suffer to be committed, any
waste upon the Premises, or any nuisance, or other act or thing which may
disturb the quiet enjoyment of any other tenant in or around the buildings in
which the subject Premises are located or allow any sale by auction upon the
Premises, or allow the Premises to be used for any improper, immoral,
unlawful or objectionable purpose, or place any loads upon the floor, walls,
or ceiling which may endanger the structure, or use any machinery or
apparatus which will in any manner vibrate or shake the Premises or the
building of which it is a part, or place any harmful liquids in the drainage
system of the building. No waste materials or refuse shall be dumped upon or
permitted to remain upon any part of the Premises outside of the building
proper. No materials, supplies, equipment, finished products or
semi-finished products, raw materials or articles of any nature shall be
stored upon or permitted to remain on any portion of the Premises outside of
the building structure, unless approved by the local, state federal or other
applicable governing authority. Lessor consents to Lessee's use of materials
which are incidental to the normal, day-to-day operations of any office user,
such as copier fluids, cleaning materials, etc., but this does not relieve
Lessee of any of its obligations not to contaminate the Premises and related
real property or violate any Hazardous Materials Laws.
4. ALTERATIONS AND ADDITIONS: Lessee shall not make, or suffer to be made, any
alteration or addition to said Premises, or any part thereof, without the
express, advance written consent of Lessor; any addition or alteration to said
Premises, except movable furniture and trade fixtures, shall become at once a
part of the realty and belong to Lessor at the end of the Lease Term or earlier
termination of this Lease. Alterations and additions which are not deemed as
trade fixtures shall include HVAC systems, lighting systems, electrical systems,
partitioning, carpeting, or any other installation which has become an integral
part of the Premises. Lessee agrees that it will not proceed to make such
alterations or additions until all required government permits have been
obtained and after having obtained consent from Lessor to do so, until five (5)
days from the receipt of such consent, so that Lessor may post appropriate
notices to avoid any liability to contractors or material suppliers for payment
for Lessee's improvements. Lessee shall at all times permit such notices to be
posted and to remain posted until the completion of work. At the end of the
Lease Term or earlier termination of this Lease, Lessee shall remove and shall
be required to remove its special tenant improvements, all related equipment,
and any additions or alterations installed by Lessee at or during the Lease Term
and Lessee shall return the Premises to the condition that existed before the
installation of the tenant improvements. Notwithstanding the above, Lessor
agrees to allow any reasonable alterations and improvements and will use its
best efforts to notify Lessee at the time of approval if such improvements or
alterations are to be removed at the end of the Lease Term or earlier
termination of this Lease.
5. MAINTENANCE OF PREMISES:
(a) Lessee shall at its sole cost and expense keep, repair, and
maintain the interior of the Premises, including, but not
limited to, all lighting systems, temperature control systems,
HVAC systems, and plumbing systems in Good Condition and Repair,
including any required replacements. Lessee shall maintain all
wall surfaces and floor coverings in Good Condition and Repair,
free of holes, gouges, or defacements and provide interior and
exterior window washing as needed. In addition, Lessee shall
keep in Good Condition and Repair the HVAC systems, including
but not limited to any HVAC systems related to any clean room
areas, by a service contract with a licensed air conditioning
and heating contractor which contract shall provide for a
minimum of quarterly maintenance of all air conditioning and
heating equipment at the Premises
Page 40
<PAGE>
including HVAC repairs or replacements which are either
excluded from such service contract or any existing
equipment warranties.
(b) Lessor shall, at Lessee's expense, keep, repair, and maintain in
Good Condition and Repair including replacements (based on a pro-rata
share of (i) costs based on square footage or (ii) costs directly
related to Lessee's use of the Premises) the following, which shall be
included in the monthly CAC:
1. The exterior of the building, any appurtenances and every
part thereof, including but not limited to, glazing, sidewalks,
parking areas, electrical systems, roof membrane, and painting
of exterior walls.
2. The landscaping by a landscape contractor to water, maintain,
trim and replace, when necessary, any shrubbery and landscaping
at the Premises.
3. The roof membrane by a service contract with a licensed
reputable roofing contractor which contract shall provide for a
minimum of semi-annual maintenance, cleaning of storm gutters,
drains, removing of debris, and trimming overhanging trees,
repair of the roof and application of a finish coat every five
years to the building at the Premises.
4. Exterior pest control.
5. Fire monitoring services.
(c) Lessee hereby waives any and all rights to make repairs at the
expense of Lessor as provided in Section 1942 of the Civil Code of the
State of California, and all rights provided for by Section 1941 of said
Civil Code.
(d) Lessor shall be responsible for the repair of any structural defects
in the Premises including the roof structure (not membrane), exterior
walls and foundation during the Lease Term.
6. INSURANCE:
A) HAZARD INSURANCE: Lessee shall not use, or permit said Premises, or
any part thereof, to be used, for any purpose other than that for which
the Premises are hereby leased; and no use shall be made or permitted to
be made of the Premises, nor acts done, which may cause a cancellation
of any insurance policy covering the Premises, or any part thereof, nor
shall Lessee sell or permit to be kept, used or sold, in or about said
Premises, any article which may be prohibited by a fire and extended
coverage insurance policy. Lessee shall comply with any and all
requirements, pertaining to said Premises, of any insurance organization
or company, necessary for the maintenance of reasonable fire and
extended coverage insurance, covering the Premises. Lessor shall, at
Lessee's sole cost and expense, purchase and keep in force fire and
extended coverage insurance, covering loss or damage to the Premises in
an amount equal to the full replacement cost of the Premises, as
determined by Lessor, with proceeds payable to Lessor. In the event of
a loss per the insurance provisions of this paragraph, Lessee shall be
responsible for deductibles up to a maximum of $5,000 per occurrence.
Lessee acknowledges that the insurance referenced in this paragraph does
not include coverage for Lessee's personal property.
B) LOSS OF RENTS INSURANCE: Lessor shall, at Lessee's sole cost and
expense, purchase and maintain in full force and effect, a policy of
rental loss insurance, in an amount equal to the amount of Rent payable
by Lessee commencing on the date of loss for the next ensuing one (1)
year, as reasonably determined by Lessor with proceeds payable to Lessor
("Loss of Rents Insurance").
Page 41
<PAGE>
C) LIABILITY AND PROPERTY DAMAGE INSURANCE: Lessee, as a material part
of the consideration to be rendered to Lessor, hereby waives all claims
against Lessor and Lessor's Agents for damages to goods, wares and
merchandise, and all other personal property in, upon, or about the
Premises, and for injuries to persons in, upon, or about the Premises,
from any cause arising at any time, and Lessee will hold Lessor and
Lessor's Agents exempt and harmless from any damage or injury to any
person, or to the goods, wares, and merchandise and all other personal
property of any person, arising from the use or occupancy of the
Premises by Lessee, or from the failure of Lessee to keep the Premises
in Good Condition and Repair, as herein provided. Lessee shall, at
Lessee's sole cost and expense, purchase and keep in force a standard
policy of commercial general liability insurance and property damage
policy covering the Premises and all related areas insuring the Lessee
having a combined single limit for both bodily injury, death and
property damage in an amount not less than five million dollars
($5,000,000.00). The limits of said insurance shall not, however, limit
the liability of Lessee hereunder. Lessee shall, at its sole cost and
expense, comply with all of the insurance requirements of all local,
municipal, state and federal authorities now in force, or which may
hereafter be in force, pertaining to Lessee's use and occupancy of the
said Premises.
D) PERSONAL PROPERTY INSURANCE: Lessee shall obtain, at Lessee's sole
cost and expense, a policy of fire and extended coverage insurance
including coverage for direct physical loss special form, and a
sprinkler leakage endorsement insuring the personal property of Lessee.
The proceeds from any personal property damage policy shall be payable
to Lessee.
All insurance policies required in 6 C) and 6 D) above shall: (i) provide for a
certificate of insurance evidencing the insurance required herein, being
deposited with Lessor ten (10) days prior to the Commencement Date, and upon
each renewal, such certificates shall be provided 30 days prior to the
expiration date of such coverage, (ii) be in a form reasonably satisfactory to
Lessor and shall provide the coverage required by Lessee in this Lease, (iii) be
carried with companies with a Best Rating of A+ minimum, (iv) specifically
provide that such policies shall not be subject to cancellation, reduction of
coverage, or other change except after 30 days prior written notice to Lessor,
and (v) name Lessor, Lessor's lender, and any other party with an insurable
interest in the Premises as additional insureds by endorsement to policy.
Lessee agrees to pay to Lessor, as additional Rent, on demand, the full cost of
the insurance polices referenced in 6 A) and 6 B) above as evidenced by
insurance billings to Lessor which shall be included in the CAC. If Lessee does
not occupy the entire Premises, the insurance premiums shall be allocated to the
portion of the Premises occupied by Lessee on a pro-rata square footage or other
equitable basis, as determined by Lessor. It is agreed that Lessee's obligation
under this paragraph shall be prorated to the reflect the Commencement Date and
the end of the Lease Term.
Lessor and Lessee hereby waive any rights each may have against the other
related to any loss or damage caused to Lessor or Lessee as the case may be, or
to the Premises or its contents, and which may arise from any risk generally
covered by fire and extended coverage insurance. The parties shall provide that
their respective insurance policies insuring the property or the personal
property include a waiver of any right of subrogation which said insurance
company may have against Lessor or Lessee, as the case may be.
7. ABANDONMENT: Lessee shall not vacate or abandon the Premises at any time
during the Lease Term; and if Lessee shall abandon, vacate or surrender said
Premises, or be dispossessed by process of law, or
Page 42
<PAGE>
otherwise, any personal property belonging to Lessee and left on the Premises
shall be deemed to be abandoned, at the option of Lessor. Notwithstanding
the above, the Premises shall not be considered vacated or abandoned if
Lessee maintains the Premises in Good Condition and Repair, provides security
and is not in default.
8. FREE FROM LIENS: Lessee shall keep the subject Premises and the property in
which the subject Premises are situated, free from any and all liens including
but not limited to liens arising out of any work performed, materials furnished,
or obligations incurred by Lessee. However, the Lessor shall allow Lessee to
contest a lien claim, so long as the claim is discharged prior to any
foreclosure proceeding being initiated against the property and provided Lessee
provides Lessor a bond if the lien exceeds $5,000.
9. COMPLIANCE WITH GOVERNMENTAL REGULATIONS: Lessee shall, at its sole cost and
expense, comply with all of the requirements of all local, municipal, state and
federal authorities now in force, or which may hereafter be in force, pertaining
to the Premises, and shall faithfully observe in the use and occupancy of the
Premises all local and municipal ordinances and state and federal statutes now
in force or which may hereafter be in force.
10. INTENTIONALLY OMITTED.
11. ADVERTISEMENTS AND SIGNS: Lessee shall not place or permit to be placed, in,
upon or about the Premises any unusual or extraordinary signs, or any signs not
approved by the city, local, state, federal or other applicable governing
authority. Lessee shall not place, or permit to be placed upon the Premises, any
signs, advertisements or notices without the written consent of the Lessor, and
such consent shall not be unreasonably withheld. A sign so placed on the
Premises shall be so placed upon the understanding and agreement that Lessee
will remove same at the end of the Lease Term or earlier termination of this
Lease and repair any damage or injury to the Premises caused thereby, and if not
so removed by Lessee, then Lessor may have the same removed at Lessee's expense.
12. UTILITIES: Lessee shall pay for all water, gas, heat, light, power,
telephone and other utilities supplied to the Premises. Any charges for sewer
usage, PG&E and telephone site service or related fees shall be the obligation
of Lessee and paid for by Lessee. If any such services are not separately
metered to Lessee, Lessee shall pay a reasonable proportion of all charges which
are jointly metered, the determination to be made by Lessor acting reasonably
and on any equitable basis. Lessor and Lessee agree that Lessor shall not be
liable to Lessee for any disruption in any of the utility services to the
Premises.
13. ATTORNEY'S FEES: In case suit should be brought for the possession of the
Premises, for the recovery of any sum due hereunder, because of the breach of
any other covenant herein, or to enforce, protect, or establish any term,
conditions, or covenant of this Lease or the right of either party hereunder,
the losing party shall pay to the Prevailing Party reasonable attorney's fees
which shall be deemed to have accrued on the commencement of such action and
shall be enforceable whether or not such action is prosecuted to judgment. The
term "Prevailing Party" shall mean the party that received substantially the
relief requested, whether by settlement, dismissal, summary judgment, judgment,
or otherwise.
14.1 DEFAULT: The occurrence of any of the following shall constitute a default
and breach of this Lease by Lessee: a) Any failure by Lessee to pay Rent or to
make any other payment required to be made by Lessee hereunder when due if not
cured within ten (10) days after written notice thereof by Lessor to Lessee; b)
Page 43
<PAGE>
The abandonment or vacation of the Premises by Lessee except as provided in
Section 7; c) A failure by Lessee to observe and perform any other provision of
this Lease to be observed or performed by Lessee, where such failure continues
for thirty days after written notice thereof by Lessor to Lessee; provided,
however, that if the nature of such default is such that the same cannot be
reasonably cured within such thirty (30) day period, Lessee shall not be deemed
to be in default if Lessee shall, within such period, commence such cure and
thereafter diligently prosecute the same to completion; d) The making by Lessee
of any general assignment for the benefit of creditors; the filing by or against
Lessee of a petition to have Lessee adjudged a bankrupt or of a petition for
reorganization or arrangement under any law relating to bankruptcy; e) the
appointment of a trustee or receiver to take possession of substantially all of
Lessee's assets or Lessee's interest in this Lease, or the attachment, execution
or other judicial seizure of substantially all of Lessee's assets located at the
Premises or of Lessee's interest in this Lease.
14.2 SURRENDER OF LEASE: In the event of any such default by Lessee, then in
addition to any other remedies available to Lessor at law or in equity, Lessor
shall have the immediate option to terminate this Lease before the end of the
Lease Term and all rights of Lessee hereunder, by giving written notice of such
intention to terminate. In the event that Lessor terminates this Lease due to a
default of Lessee, then Lessor may recover from Lessee: a) the worth at the time
of award of any unpaid Rent which had been earned at the time of such
termination; plus b) the worth at the time of award of unpaid Rent which would
have been earned after termination until the time of award exceeding the amount
of such rental loss that the Lessee proves could have been reasonably avoided;
plus c) the worth at the time of award of the amount by which the unpaid Rent
for the balance of the Lease Term after the time of award exceeds the amount of
such rental loss that the Lessee proves could have been reasonably avoided; plus
d) any other amount necessary to compensate Lessor for all the detriment
proximately caused by Lessee's failure to perform his obligations under this
Lease or which in the ordinary course of things would be likely to result
therefrom; and e) at Lessor's election, such other amounts in addition to or in
lieu of the foregoing as may be permitted from time to time by applicable
California law. As used in (a) and (b) above, the "worth at the time of award"
is computed by allowing interest at the rate of Wells Fargo's prime rate plus
two percent (2%) per annum. As used in (c) above, the "worth at the time of
award" is computed by discounting such amount at the discount rate of the
Federal Reserve Bank of San Francisco at the time of award plus one percent
(1%).
14.3 RIGHT OF ENTRY AND REMOVAL: In the event of any such default by Lessee,
Lessor shall also have the right, with or without terminating this Lease, to
re-enter the Premises and remove all persons and property from the Premises;
such property may be removed and stored in a public warehouse or elsewhere at
the cost of and for the account of Lessee.
14.4 ABANDONMENT: In the event of the vacation or abandonment, except as
provided in Section 7, of the Premises by Lessee or in the event that Lessor
shall elect to re-enter as provided in paragraph 14.3 above or shall take
possession of the Premises pursuant to legal proceeding or pursuant to any
notice provided by law, and Lessor does not elect to terminate this Lease as
provided in Section 14.2 above, then Lessor may from time to time, without
terminating this Lease, either recover all Rent as it becomes due or relet the
Premises or any part thereof for such term or terms and at such rental rates and
upon such other terms and conditions as Lessor, in its sole discretion, may deem
advisable with the right to make alterations and repairs to the Premises. In
the event that Lessor elects to relet the Premises, then Rent received by Lessor
from such reletting shall be applied; first, to the payment of any indebtedness
other than Rent due hereunder from Lessee to Lessor; second, to the payment of
any cost of such reletting; third, to the
Page 44
<PAGE>
payment of the cost of any alterations and repairs to the Premises; fourth,
to the payment of Rent due and unpaid hereunder; and the residue, if any,
shall be held by Lessor and applied to the payment of future Rent as the same
may become due and payable hereunder. Should that portion of such Rent
received from such reletting during any month, which is applied by the
payment of Rent hereunder according to the application procedure outlined
above, be less than the Rent payable during that month by Lessee hereunder,
then Lessee shall pay such deficiency to Lessor immediately upon demand
therefor by Lessor. Such deficiency shall be calculated and paid monthly.
Lessee shall also pay to Lessor, as soon as ascertained, any costs and
expenses incurred by Lessor in such reletting or in making such alterations
and repairs not covered by the rentals received from such reletting.
14.5 NO IMPLIED TERMINATION: No re-entry or taking possession of the Premises by
Lessor pursuant to Section 14.3 or Section 14.4 of this Lease shall be construed
as an election to terminate this Lease unless a written notice of such intention
is given to Lessee or unless the termination thereof is decreed by a court of
competent jurisdiction. Notwithstanding any reletting without termination by
Lessor because of any default by Lessee, Lessor may at any time after such
reletting elect to terminate this Lease for any such default.
15. SURRENDER OF LEASE: The voluntary or other surrender of this Lease by
Lessee, or a mutual cancellation thereof, shall not work a merger, and shall, at
the option of Lessor, terminate all or any existing subleases or sub tenancies,
or may, at the option of Lessor, operate as an assignment to him of any or all
such subleases or sub tenancies.
16. TAXES: Lessee shall pay and discharge punctually and when the same shall
become due and payable without penalty, all real estate taxes, personal property
taxes, taxes based on vehicles utilizing parking areas in the Premises, taxes
computed or based on rental income (other than federal, state and municipal net
income taxes), environmental surcharges, privilege taxes, excise taxes, business
and occupation taxes, school fees or surcharges, gross receipts taxes, sales
and/or use taxes, employee taxes, occupational license taxes, water and sewer
taxes, assessments (including, but not limited to, assessments for public
improvements or benefit), assessments for local improvement and maintenance
districts, and all other governmental impositions and charges of every kind and
nature whatsoever, regardless of whether now customary or within the
contemplation of the parties hereto and regardless of whether resulting from
increased rate and/or valuation, or whether extraordinary or ordinary, general
or special, unforeseen or foreseen, or similar or dissimilar to any of the
foregoing (all of the foregoing being hereinafter collectively called "Tax" or
"Taxes") which, at any time during the Lease Term, shall be applicable or
against the Premises, or shall become due and payable and a lien or charge upon
the Premises under or by virtue of any present or future laws, statutes,
ordinances, regulations, or other requirements of any governmental authority
whatsoever. The term "Environmental Surcharge" shall include any and all
expenses, taxes, charges or penalties imposed by the Federal Department of
Energy, Federal Environmental Protection Agency, the Federal Clean Air Act, or
any regulations promulgated thereunder, or any other local, state or federal
governmental agency or entity now or hereafter vested with the power to impose
taxes, assessments or other types of surcharges as a means of controlling or
abating environmental pollution or the use of energy in regard to the use,
operation or occupancy of the Premises. The term "Tax" shall include, without
limitation, all taxes, assessments, levies, fees, impositions or charges levied,
imposed, assessed, measured, or based in any manner whatsoever (i) in whole or
in part on the Rent payable by Lessee under this Lease, (ii) upon or with
respect to the use, possession, occupancy, leasing, operation or management of
the Premises, (iii) upon this transaction or any document to which Lessee is a
party creating or transferring an
Page 45
<PAGE>
interest or an estate in the Premises, (iv) upon Lessee's business operations
conducted at the Premises, (v) upon, measured by or reasonably attributable
to the cost or value of Lessee's equipment, furniture, fixtures and other
personal property located on the Premises or the cost or value of any
leasehold improvements made in or to the Premises by or for Lessee,
regardless of whether title to such improvements shall be in Lessor or
Lessee, or (vi) in lieu of or equivalent to any Tax set forth in this Section
16. In the event any such Taxes are payable by Lessor and it shall not be
lawful for Lessee to reimburse Lessor for such Taxes, then the Rent payable
thereunder shall be increased to net Lessor the same net rent after
imposition of any such Tax upon Lessor as would have been payable to Lessor
prior to the imposition of any such Tax. It is the intention of the parties
that Lessor shall be free from all such Taxes and all other governmental
impositions and charges of every kind and nature whatsoever. However,
nothing contained in this Section 16 shall require Lessee to pay any Federal
or State income, franchise, estate, inheritance, succession, transfer or
excess profits tax imposed upon Lessor. If any general or special
assessment is levied and assessed against the Premises, Lessor agrees to use
its best reasonable efforts to cause the assessment to become a lien on the
Premises securing repayment of a bond sold to finance the improvements to
which the assessment relates which is payable in installments of principal
and interest over the maximum term allowed by law. It is understood and
agreed that Lessee's obligation under this paragraph will be prorated to
reflect the Commencement Date and the end of the Lease Term. It is further
understood that if Taxes cover the Premises and Lessee does not occupy the
entire Premises, the Taxes will be allocated to the portion of the Premises
occupied by Lessee based on a pro-rata square footage or other equitable
basis, as determined by Lessor. Taxes billed by Lessor to Lessee shall be
included in the monthly CAC.
Subject to any limitations or restrictions imposed by any deeds of trust or
mortgages now or hereafter covering or affecting the Premises, Lessee shall have
the right to contest or review the amount or validity of any Tax by appropriate
legal proceedings but which is not to be deemed or construed in any way as
relieving, modifying or extending Lessee's covenant to pay such Tax at the time
and in the manner as provided in this Section 16. However, as a condition of
Lessee's right to contest, if such contested Tax is not paid before such contest
and if the legal proceedings shall not operate to prevent or stay the collection
of the Tax so contested, Lessee shall, before instituting any such proceeding,
protect the Premises and the interest of Lessor and of the beneficiary of a deed
of trust or the mortgagee of a mortgage affecting the Premises against any lien
upon the Premises by a surety bond, issued by an insurance company acceptable to
Lessor and in an amount equal to one and one-half (1 1/2) times the amount
contested or, at Lessor's option, the amount of the contested Tax and the
interest and penalties in connection therewith. Any contest as to the validity
or amount of any Tax, whether before or after payment, shall be made by Lessee
in Lessee's own name, or if required by law, in the name of Lessor or both
Lessor and Lessee. Lessee shall defend, indemnify and hold harmless Lessor
from and against any and all costs or expenses, including attorneys' fees, in
connection with any such proceedings brought by Lessee, whether in its own name
or not. Lessee shall be entitled to retain any refund of any such contested Tax
and penalties or interest thereon which have been paid by Lessee. Nothing
contained herein shall be construed as affecting or limiting Lessor's right to
contest any Tax at Lessor's expense.
17. NOTICES: Unless otherwise provided for in this Lease, any and all written
notices or other communication (the "Communication") to be given in connection
with this Lease shall be given in writing and shall be given by personal
delivery, facsimile transmission or by mailing by registered or certified mail
with postage thereon or recognized overnight courier, fully prepaid, in a sealed
envelope addressed to the intended recipient as follows:
Page 46
<PAGE>
(a) to the Lessor at: 10050 Bandley Drive
Cupertino, California 95014
Attention: Carl E. Berg
Fax No: (408) 725-1626
(b) to the Lessee at: 1190 Morse
Sunnyvale, California
Attention: _______________
Fax No: _______________
or such other addresses, facsimile number or individual as may be designated by
a Communication given by a party to the other parties as aforesaid. Any
Communication given by personal delivery shall be conclusively deemed to have
been given and received on a date it is so delivered at such address provided
that such date is a business day, otherwise on the first business day following
its receipt, and if given by registered or certified mail, on the day on which
delivery is made or refused or if given by recognized overnight courier, on the
first business day following deposit with such overnight courier and if given by
facsimile transmission, on the day on which it was transmitted provided such day
is a business day, failing which, on the next business day thereafter.
18. ENTRY BY LESSOR: Lessee shall permit Lessor and its agents to enter into and
upon said Premises at all reasonable times using the minimum amount of
interference and inconvenience to Lessee and Lessee's business, subject to any
security regulations of Lessee, for the purpose of inspecting the same or for
the purpose of maintaining the building in which said Premises are situated, or
for the purpose of making repairs, alterations or additions to any other portion
of said building, including the erection and maintenance of such scaffolding,
canopies, fences and props as may be required, without any rebate of Rent and
without any liability to Lessee for any loss of occupation or quiet enjoyment of
the Premises; and shall permit Lessor and his agents, at any time within ninety
(90) days prior to the end of the Lease Term, to place upon said Premises any
usual or ordinary "For Sale" or "For Lease" signs and exhibit the Premises to
prospective tenants at reasonable hours.
19. DESTRUCTION OF PREMISES: In the event of a partial destruction of the
said Premises during the Lease Term from any cause which is covered by
Lessor's property insurance, Lessor shall forthwith repair the same, provided
such repairs can be made within ninety (90) days after receipt of building
permit under the laws and regulations of State, Federal, County, or Municipal
authorities, but such partial destruction shall in no way annul or void this
Lease, except that Lessee shall be entitled to a proportionate reduction of
Rent while such repairs are being made to the extent of payments received by
Lessor under its Loss of Rents Insurance coverage. With respect to any
partial destruction which Lessor is obligated to repair or may elect to
repair under the terms of this paragraph, the provision of Section 1932,
Subdivision 2, and of Section 1933, Subdivision 4, of the Civil Code of the
State of California are awived by Lessee. In the event that the building in
which the subject Premises may be situated is destroyed to an extent greater
than thirty-three and one-third percent (33 1/3%) of the replacement cost
thereof, Lessor may, at its sole option, elect to terminate this Lease,
whether the subject Premises is insured or not. A total destruction of the
building in which the subject Premises are situated shall terminate this
Lease. Notwithstanding the above, Lessor is only obligated to repair or
rebuild to the extent of available insurance proceeds including any
deductible amount. Should Lessor determine that insufficient or no insurance
proceeds are available for repair or
Page 47
<PAGE>
reconstruction of Premises, Lessor, at its sole option, may terminate the
Lease. Lessee shall have the option of continuing this Lease by agreeing to
pay all repair costs to the subject Premises.
20. ASSIGNMENT AND SUBLETTING: Lessee shall not assign this Lease, or any
interest therein, and shall not sublet the said Premises or any part thereof,
or any right or privilege appurtenant thereto, or cause any other person or
entity (a bona fide subsidiary or affiliate of Lessee excepted) to occupy or
use the Premises, or any portion thereof, without the advance written consent
of Lessor. Any such assignment or subletting without such consent shall be
void, and shall, at the option of the Lessor, terminate this Lease. This
Lease shall not, or shall any interest therein, be assignable, as to the
interest of Lessee, by operation of law, without the written consent of
Lessor. Notwithstanding Lessor's obligation to provide reasonable approval,
Lessor reserves the right to withhold its consent for any proposed sublessee
or assignee of Lessee if the proposed sublessee or assignee is a user or
generator of Hazardous Materials. Notwithstanding the foregoing, Lessee may
assign up to 12,000 square feet of this Lease, provided there is no
substantial reduction in the net worth of the resulting entity and the
resulting entity is not the user or generator of Hazardous Materials.
Whether or not Lessor's consent to a sublease or assignment is required, in
the event of any sublease or assignment, Lessee shall be and shall remain
primarily liable for the performance of all conditions, covenants, and
obligations of Lessee hereunder and, in the event of a default by an assignee
or sublessee, Lessor may proceed directly against the original Lessee
hereunder and/or any other predecessor of such assignee or sublessee without
the necessity of exhausting remedies against said assignee or sublessee.
21. CONDEMNATION: If any part of the Premises shall be taken for any public
or quasi-public use, under any statute or by right of eminent domain or
private purchase in lieu thereof, and a part thereof remains which is
susceptible of occupation hereunder, this Lease shall as to the part so
taken, terminate as of the date title vests in the condemnor or purchaser,
and the Rent payable hereunder shall be adjusted so that the Lessee shall be
required to pay for the remainder of the Lease Term only that portion of Rent
as the value of the part remaining. The rental adjustment resulting will be
computed at the same Rental rate for the remaining part not taken; however,
Lessor shall have the option to terminate this Lease as of the date when
title to the part so taken vests in the condemnor or purchaser. If all of
the Premises, or such part thereof be taken so that there does not remain a
portion susceptible for occupation hereunder, this Lease shall thereupon
terminate. If a part or all of the Premises be taken, all compensation
awarded upon such taking shall be payable to the Lessor. Lessee may file a
separate claim and be entitled to any award granted to Lessee.
22. EFFECTS OF CONVEYANCE: The term "Lessor" as used in this Lease, means only
the owner for the time being of the land and building constituting the Premises,
so that, in the event of any sale of said land or building, or in the event of a
Lease of said building, Lessor shall be and hereby is entirely freed and
relieved of all covenants and obligations of Lessor hereunder, and it shall be
deemed and construed, without further agreement between the parties and the
purchaser of any such sale, or the Lessor of the building, that the purchaser or
lessor of the building has assumed and agreed to carry out any and all covenants
and obligations of the Lessor hereunder. If any security is given by Lessee to
secure the faithful performance of all or any of the covenants of this Lease on
the part of Lessee, Lessor may transfer and deliver the security, as such, to
the purchaser at any such sale of the building, and thereupon the Lessor shall
be discharged from any further liability.
23. SUBORDINATION: This Lease, in the event Lessor notifies Lessee in writing,
shall be subordinate to any ground lease, deed of trust, or other hypothecation
for security now or hereafter placed upon the real
Page 48
<PAGE>
property at which the Premises are a part and to any and all advances made on
the security thereof and to renewals, modifications, replacements and
extensions thereof. Lessee agrees to promptly execute any documents which may
be required to effectuate such subordination. Notwithstanding such
subordination, if Lessee is not in default and so long as Lessee shall pay
the Rent and observe and perform all of the provisions and covenants required
under this Lease, Lessee's right to quiet possession of the Premises shall
not be disturbed or effected by any subordination.
24. WAIVER: The waiver by Lessor of any breach of any term, covenant or
condition, herein contained shall not be construed to be a waiver of such term,
covenant or condition or any subsequent breach of the same or any other term,
covenant or condition therein contained. The subsequent acceptance of Rent
hereunder by Lessor shall not be deemed to be a waiver of Lessee's breach of any
term, covenant, or condition of the Lease.
25. HOLDING OVER: Any holding over after the end of the Lease Term requires
Lessor's written approval prior to the end of the Lease Term, which,
notwithstanding any other provisions of this Lease, Lessor may withhold. Such
holding over shall be construed to be a tenancy at sufferance from month to
month. Lessee shall pay to Lessor monthly base rent equal to one and one-half
(1.5) times the monthly base rent installment due in the last month of the Lease
Term and all other additional rent and all other terms and conditions of the
Lease shall apply, so far as applicable. Holding over by Lessee without written
approval of Lessor shall subject Lessee to the liabilities and obligations
provided for in this Lease and by law, including, but not limited to those in
Section 2 of this Lease. Lessee shall indemnify and hold Lessor harmless
against any loss or liability resulting from any delay caused by Lessee in
surrendering the Premises, including without limitation, any claims made or
penalties incurred by any succeeding lessee or by Lessor. No holding over shall
be deemed or construed to exercise any option to extend or renew this Lease in
lieu of full and timely exercise of any such option as required hereunder.
26. LESSOR'S LIABILITY: If Lessee should recover a money judgment against Lessor
arising in connection with this Lease, the judgment shall be satisfied only out
of the Lessor's interest in the Premises and neither Lessor or any of its
partners shall be liable personally for any deficiency.
27. ESTOPPEL CERTIFICATES: Lessee shall at any time during the Lease Term, upon
not less than ten (10) days prior written notice from Lessor, execute and
deliver to Lessor a statement in writing certifying that, this Lease is
unmodified and in full force and effect (or, if modified, stating the nature of
such modification) and the dates to which the Rent and other charges have been
paid in advance, if any, and acknowledging that there are not, to Lessee's
knowledge, any uncured defaults on the part of Lessor hereunder or specifying
such defaults if they are claimed. Any such statement may be conclusively
relied upon by any prospective purchaser or encumbrancer of the Premises.
Lessee's failure to deliver such a statement within such time shall be
conclusive upon the Lessee that (a) this Lease is in full force and effect,
without modification except as may be represented by Lessor; (b) there are no
uncured defaults in Lessor's performance.
28. TIME: Time is of the essence of the Lease.
29. CAPTIONS: The headings on titles to the paragraphs of this Lease are not a
part of this Lease and shall have no effect upon the construction or
interpretation of any part thereof. This instrument contains all of the
agreements and conditions made between the parties hereto and may not be
modified orally or in any
Page 49
<PAGE>
other manner than by an agreement in writing signed by all of the parties
hereto or their respective successors in interest.
30. PARTY NAMES: Landlord and Tenant may be used in various places in this Lease
as a substitute for Lessor and Lessee respectively.
31. EARTHQUAKE INSURANCE: As a condition of Lessor agreeing to waive the
requirement for earthquake insurance, Lessee agrees that it will pay, as
additional Rent, which shall be included in the monthly CAC, an amount not to
exceed Eleven Thousand Three Hundred Forty Dollars ($11,340) per year for
earthquake insurance if Lessor desires to obtain some form of earthquake
insurance in the future, if and when available, on terms acceptable to Lessor as
determined in the sole and absolute discretion of Lessor.
32. HABITUAL DEFAULT: Notwithstanding anything to the contrary contained in
Section 14 herein, Lessor and Lessee agree that if Lessee shall have
defaulted in the payment of Rent for three or more times during any twelve
month period during the Lease Term, then such conduct shall, at the option of
the Lessor, represent a separate event of default which cannot be cured by
Lessee. Lessee acknowledges that the purpose of this provision is to prevent
repetitive defaults by the Lessee under the Lease, which constitute a
hardship to the Lessor and deprive the Lessor of the timely performance by
the Lessee hereunder.
33. HAZARDOUS MATERIALS
33.1 DEFINITIONS: As used in this Lease, the following terms shall have the
following meaning:
a. The term "Hazardous Materials" shall mean (i) polychlorinated
biphenyls; (ii) radioactive materials and (iii) any chemical, material
or substance now or hereafter defined as or included in the
definitions of "hazardous substance" "hazardous water", "hazardous
material", "extremely hazardous waste", "restricted hazardous waste"
under Section 25115, 25117 or 15122.7, or listed pursuant to Section
25140 of the California Health and Safety Code, Division 20, Chapter
6.5 (Hazardous Waste Control Law), (ii) defined as "hazardous
substance" under Section 25316 of the California Health and Safety
Code, Division 20, Chapter 6.8 (Carpenter-Presley-Tanner Hazardous
Substances Account Act), (iii) defined as "hazardous material",
"hazardous substance", or "hazardous waste" under Section 25501 of the
California Health and Safety Code, Division 20, Chapter 6.95
(Hazardous Materials Release, Response, Plans and Inventory), (iv)
defined as a "hazardous substance" under Section 25181 of the
California Health and Safety Code, Division 20l, Chapter 6.7
(Underground Storage of Hazardous Substances), (v) petroleum, (vi)
asbestos, (vii) listed under Article 9 or defined as "hazardous" or
"extremely hazardous" pursuant to Article II of Title 22 of the
California Administrative Code, Division 4, Chapter 20, (viii) defined
as "hazardous substance" pursuant to Section 311 of the Federal Water
Pollution Control Act, 33 U.S.C. 1251 et seq. or listed pursuant to
Section 1004 of the Federal Water Pollution Control Act (33 U.S.C.
1317), (ix) defined as a "hazardous waste", pursuant to Section 1004
of the Federal Resource Conservation and Recovery Act, 42 U.S.C. 6901
et seq., (x) defined as "hazardous substance" pursuant to Section 101
of the Comprehensive Environmental Responsibility Compensations, and
Liability Act, 42 U.S.C. 9601 et seq., or (xi) regulated under the
Toxic Substances Control Act, 156 U.S.C. 2601 et seq.
b. The term "Hazardous Materials Laws" shall mean any local,
state and federal laws, rules, regulations, or ordinances relating to
the use, generation, transportation, analysis, manufacture, installation,
release, discharge, storage or disposal of Hazardous Material.
Page 50
<PAGE>
c. The term "Lessor's Agents" shall mean Lessor's agents,
representatives, employees, contractors, subcontractors, directors,
officers and partners.
d. The term "Lessee's Agents" shall mean Lessee's agents,
representatives, employees, contractors, subcontractors, directors,
officers, partners, invitees or any other person in or about the
Premises.
33.2 LESSEE'S RIGHT TO INVESTIGATE: Lessee shall be entitled to cause such
inspection, soils and ground water tests, and other evaluations to be made of
the Premises as Lessee deems necessary regarding (i) the presence and use of
Hazardous Materials in or about the Premises, and (ii) the potential for
exposure to Lessee's employees and other persons to any Hazardous Materials used
and stored by previous occupants in or about the Premises. Lessee shall provide
Lessor with copies of all inspections, tests and evaluations. Lessee shall
indemnify, defend and hold Lessor harmless from any cost, claim or expense
arising from such entry by Lessee or from the performance of any such
investigation by such Lessee.
33.3 LESSOR'S REPRESENTATIONS: Lessor hereby represents and warrants to the best
of Lessor's knowledge that the Premises are, as of the date of this Lease, in
compliance with all Hazardous Material Laws.
33.4 LESSEE'S OBLIGATION TO INDEMNIFY: Lessee, at its sole cost and expense,
shall indemnify, defend, protect and hold Lessor and Lessor's Agents harmless
from and against any and all cost or expenses, including those described under
subparagraphs i, ii and iii herein below set forth, arising from or caused in
whole or in part, directly or indirectly by:
a. Lessee's or Lessee's Agents' use, analysis, storage, transportation,
disposal, release, threatened release, discharge or generation of
Hazardous Material to, in, on, under, about or from the Premises; or
b. Lessee's or Lessee's Agents failure to comply with Hazardous Material
laws; or
c. Any release of Hazardous Material to, in, on, under, about, from or
onto the Premises caused by or occurring as a result of acts or
omissions of Lessee or Lessee's Agents or occurring during the Lease
Term, except ground water contamination from other parcels where the
source is from off the Premises not arising from or caused by Lessee or
Lessee's Agents.
The cost and expenses indemnified against include, but are not limited to the
following:
i. Any and all claims, actions, suits, proceedings, losses, damages,
liabilities, deficiencies, forfeitures, penalties, fines, punitive
damages, cost or expenses;
ii. Any claim, action, suit or proceeding for personal injury (including
sickness, disease, or death), tangible or intangible property damage,
compensation for lost wages, business income, profits or other economic
loss, damage to the natural resources of the environment, nuisance,
pollution, contamination, leaks, spills, release or other adverse
effects on the environment;
iii. The cost of any repair, clean-up, treatment or detoxification of
the Premises necessary to bring the Premises into compliance with all
Hazardous Material Laws, including the preparation and implementation of
any closure, disposal, remedial action, or other actions with regard to
the Premises, and expenses (including, without limitation, reasonable
attorney's fees and consultants fees, investigation and laboratory fees,
court cost and litigation expenses).
33.5 LESSEE'S OBLIGATION TO REMEDIATE CONTAMINATION: Lessee shall, at its sole
cost and expense, promptly take any and all action necessary to remediate
contamination of the Premises by Hazardous Materials during the Lease Term.
Page 51
<PAGE>
33.6 OBLIGATION TO NOTIFY: Lessor and Lessee shall each give written notice to
the other as soon as reasonably practical of (i) any communication received from
any governmental authority concerning Hazardous Material which related to the
Premises and (ii) any contamination of the Premises by Hazardous Materials which
constitutes a violation of any Hazardous Material Laws.
33.7 SURVIVAL: The obligations of Lessee under this Section 33 shall survive the
Lease Term or earlier termination of this Lease.
33.8 CERTIFICATION AND CLOSURE: On or before the end of the Lease Term or
earlier termination of this Lease, Lessee shall deliver to Lessor a
certification executed by Lessee stating that, to the best of Lessee's
knowledge, there exists no violation of Hazardous Material Laws resulting from
Lessee's obligation in Paragraph 33. If pursuant to local ordinance, state or
federal law, Lessee is required, at the expiration of the Lease Term, to submit
a closure plan for the Premises to a local, state or federal agency, then Lessee
shall furnish to Lessor a copy of such plan.
33.9 PRIOR HAZARDOUS MATERIALS: Lessee shall have no obligation to clean up or
to hold Lessor harmless with respect to, any Hazardous Material or wastes
discovered on the Premises which were not introduced into, in, on, about, from
or under the Premises during the Lease Term or ground water contamination from
other parcels where the source is from off the Premises not arising from or
caused by Lessee or Lessee's Agents.
34. BROKERS: Lessor and Lessee represent that they have not utilized or
contacted a real estate broker or finder with respect to this Lease other than
Bishop Hawk, Inc. ("BH") and Lessee agrees to indemnify and hold Lessor harmless
against any claim, cost, liability or cause of action asserted by any broker or
finder claiming through Lessee other than BH. Lessor shall at its sole cost and
expense pay the brokerage commission per Lessee's standard commission schedule
to BH in connection with this transaction. Lessor represents and warrants that
it has not utilized or contacted a real estate broker or finder with respect to
this Lease other than BH and Lessor agrees to indemnify and hold Lessee harmless
against any claim, cost, liability or cause of action asserted by any broker or
finder claiming through Lessor.
35. OPTION TO EXTEND
A. OPTION: Lessor hereby grants to Lessee one (1) option to extend the Lease
Term, with the extended term to be for a period of five (5) years, on the
following terms and conditions:
(i) Lessee shall give Lessor written notice of its exercise of its
option to extend no earlier than twenty-four (24) calendar months, nor
later than six (6) calendar months before the Lease Term would end but
for said exercise. Time is of the essence.
(ii) Lessee may not extend the Lease Term pursuant to any option granted
by this Section 35 if Lessee is in default as of the date of the
exercise of its option. If Lessee has committed a default by Lessee as
defined in Section 14 or 32 that has not been cured or waived by Lessor
in writing by the date that any extended term is to commence, then
Lessor may elect not to allow the Lease Term to be extended,
notwithstanding any notice given by Lessee of an exercise of this option
to extend.
Page 52
<PAGE>
(iii) All terms and conditions of this Lease shall apply during the
extended term, except that the base rent and rental increases for each
extended term shall be determined as provided in Section 35 (B) below
(iv) Lessee must provide Lessor written notice of its exercise of its
option as provided hereunder at least nine (9) months before the Lease
Term would end but for said exercise for purposes of negotiating rental
terms. Lessee may withdraw its notice of exercise of an extension
option for any reason prior to six (6) months before the Lease Term
would end but for said exercise. Lessor shall provide Lessee with
Lessor's proposed base monthly rent for the option period within twenty
(20) days of Lessee's written request. However, once Lessee delivers a
notice of exercise of an option to extend the Lease Term it may not be
withdrawn unless notice in writing is provided to Lessor at least six
(6) months before the Lease Term would end but for said exercise and,
subject to the provisions of this Section 35, such notice shall operate
to extend the Lease Term. Upon any extension of the Lease Term
pursuant to this Section 35, the term "Lease Term" as used in this Lease
shall thereafter include the then extended term.
(v) The option rights of Coptech West granted under this Section 35 are
granted for Coptect West's personal benefit and may not be assigned or
transferred by Coptech West or exercised if Coptech West is not
occupying the Premises at the time of exercise.
B. EXTENDED TERM RENT - OPTION PERIOD: The monthly Rent for the Premises during
the extended term shall equal the fair market monthly Rent for the Premises as
of the commencement date of the extended term, but in no case, less than the
Rent during the last month of the prior Lease term. Promptly upon Lessee's
exercise of the option to extend, Lessee and Lessor shall meet and attempt to
agree on the fair market monthly Rent for the Premises as of the commencement
date of the extended term. In the event the parties fail to agree upon the
amount of the monthly Rent for the extended term prior to commencement thereof,
the monthly Rent for the extended term shall be determined by appraisal in the
manner hereafter set forth; provided, however, that in no event shall the
monthly Rent for the extended term be less than in the immediate preceding
period. Annual base rent increases during the extended term shall be three
percent (3%) per year. In the event it becomes necessary under this paragraph
to determine the fair market monthly Rent of the Premises by appraisal, Lessor
and Lessee each shall appoint a real estate appraiser who shall be a member of
the American Institute of Real Estate Appraiser ("AIREA") and such appraisers
shall each determine the fair market monthly Rent for the Premises taking into
account the value of the Premises and the amenities provided by the outside
areas, the common areas, and the Building, and prevailing comparable Rentals in
the area. Such appraisers shall, within twenty (20) business days after their
appointment, complete their appraisals and submit their appraisal reports to
Lessor and Lessee. If the fair market monthly Rent of the Premises established
in the two (2) appraisals varies by five percent (5%) or less of the higher
Rent, the average of the two shall be controlling. If said fair market monthly
Rent varies by more than five percent (5%) of the higher Rental, said
appraisers, within ten (10) days after submission of the last appraisal, shall
appoint a third appraiser who shall be a member of the AIREA and who shall also
be experienced in the appraisal of Rent values and adjustment practices for
commercial properties in the vicinity of the Premises. Such third appraiser
shall, within twenty (20) business days after his appointment, determine by
appraisal the fair market monthly Rent of the Premises taking into account the
same factors referred to above, and submit his appraisal report to Lessor and
Lessee. The fair market monthly Rent determined by the third appraiser for the
Premises shall be controlling, unless it is less than that set forth in the
lower appraisal previously obtained, in which case the value set forth in said
lower
Page 53
<PAGE>
appraisal shall be controlling, or unless it is greater than that set
forth in the higher appraisal previously obtained in which case the Rent set for
in said higher appraisal shall be controlling. If either Lessor or Lessee fails
to appoint an appraiser, or if an appraiser appointed by either of them fails,
after his appointment to submit his appraisal within the required period in
accordance with the foregoing, the appraisal submitted by the appraiser properly
appointed and timely submitting his appraisal shall be controlling. If the two
appraisers appointed by Lessor and Lessee are unable to agree upon a third
appraiser within the required period in accordance with the foregoing,
application shall be made within twenty (20) days thereafter by either Lessor or
Lessee to AIREA, which shall appoint a member of said institute willing to serve
as appraiser. The cost of all appraisals under this subparagraph shall be borne
equally be Lessor and Lessee.
36. APPROVALS: Whenever in this Lease the Lessor's or Lessee's consent is
required, such consent shall not be unreasonably or arbitrarily withheld or
delayed. In the event that the Lessor or Lessee does not respond to a request
for any consents which may be required of it in this Lease within ten business
days of the request of such consent in writing by the Lessee or Lessor, such
consent shall be deemed to have been given by the Lessor or Lessee.
37. AUTHORITY: Each party executing this Lease represents and warrants that
he or she is duly authorized to execute and deliver the Lease. If executed
on behalf of a corporation, that the Lease is executed in accordance with the
by-laws of said corporation (or a partnership that the Lease is executed in
accordance with the partnership agreement of such partnership), that no other
party's approval or consent to such execution and delivery is required, and
that the Lease is binding upon said individual, corporation (or partnership)
as the case may be in accordance with its terms.
38. INDEMNIFICATION OF LESSOR: Except to the extent caused by the sole
negligence or willful misconduct of Lessor or Lessor's Agents, Lessee shall
defend, indemnify and hold Lessor harmless from and against any and all
obligations, losses, costs, expenses, claims, demands, attorney's fees,
investigation costs or liabilities on account of, or arising out of the use,
condition or occupancy of the Premises or any act or omission to act of Lessee
or Lessee's Agents or any occurrence in, upon, about or at the Premises,
including, without limitation, any of the foregoing provisions arising out of
the use, generation, manufacture, installation, release, discharge, storage, or
disposal of Hazardous Materials by Lessee or Lessee's Agents. It is understood
that Lessee is and shall be in control and possession of the Premises and that
Lessor shall in no event be responsible or liable for any injury or damage or
injury to any person whatsoever, happening on, in, about, or in connection with
the Premises, or for any injury or damage to the Premises or any part thereof.
This Lease is entered into on the express condition that Lessor shall not be
liable for, or suffer loss by reason of injury to person or property, from
whatever cause, which in any way may be connected with the use, condition or
occupancy of the Premises or personal property located herein. The provisions of
this Lease permitting Lessor to enter and inspect the Premises are for the
purpose of enabling Lessor to become informed as to whether Lessee is complying
with the terms of this Lease and Lessor shall be under no duty to enter, inspect
or to perform any of Lessee's covenants set forth in this Lease. Lessee shall
further indemnify, defend and hold harmless Lessor from and against any and all
claims arising from any breach or default in the performance of any obligation
to Lessee's part to be performed under the terms of this Lease. The provisions
of Section 38 shall survive the Lease Term or earlier termination of this Lease
with respect to any damage, injury or death occurring during the Lease Term.
Page 54
<PAGE>
39. SUCCESSORS AND ASSIGNS: The covenants and conditions herein contained shall,
subject to the provisions as to assignment, apply to and bind the heirs,
successors, executors, administrators and assigns of all of the parties hereto;
and all of the parties hereto shall be jointly and severally liable hereunder.
40. MISCELLANEOUS PROVISIONS: All rights and remedies hereunder are cumulative
and not alternative to the extent permitted by law and are in addition to all
other rights or remedies in law and in equity.
41. CHOICE OF LAW: This lease shall be construed and enforced in accordance
with the substantive laws of the State of California. The language of all parts
of this lease shall in all cases be construed as a whole according to its fair
meaning and not strictly for or against either Lessor or Lessee.
42. ENTIRE AGREEMENT: This Lease is the entire agreement between the parties,
and there are no agreements or representations between the parties except as
expressed herein. Except as otherwise provided for herein, no subsequent change
or addition to this Lease shall be binding unless in writing and signed by the
parties hereto.
IN WITNESS WHEREOF, Lessor and Lessee have executed these presents, the day and
year first above written.
LESSOR LESSEE
BERG & BERG ENTERPRISES, INC. COPTECH WEST
By: /s/ Carl E. Berg By: /s/ Frank M. Veloz
------------------------ ----------------------------------
signature of authorized signature of authorized representative
representative
Carl E. Berg Frank M. Veloz
- --------------------------- --------------------------------------
printed name printed name
President President
- -------------------------- --------------------------------------
title title
5/8/97 5/8/97
- ------------------------- --------------------------------------
date date
Page 55
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> MAR-31-1998
<CASH> 8,886,000
<SECURITIES> 6,978,000
<RECEIVABLES> 186,000
<ALLOWANCES> 0
<INVENTORY> 553,000
<CURRENT-ASSETS> 67,000
<PP&E> 1,202,000
<DEPRECIATION> (688,000)
<TOTAL-ASSETS> 17,184,000
<CURRENT-LIABILITIES> (1,372,000)
<BONDS> 0
0
0
<COMMON> (10,000)
<OTHER-SE> (15,802,000)
<TOTAL-LIABILITY-AND-EQUITY> (17,184,000)
<SALES> 320,000
<TOTAL-REVENUES> 320,000
<CGS> (289,000)
<TOTAL-COSTS> (2,422,000)
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (2,034,000)
<INCOME-TAX> 0
<INCOME-CONTINUING> (2,034,000)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,034,000)
<EPS-PRIMARY> $(0.39)
<EPS-DILUTED> $(0.39)
</TABLE>
